Brand Name |
Generic Name |
Therapeutic Area |
Recommendation Type |
Project Status |
Date Submission Received |
Date Recommendation Issued |
Proyect name |
Gynazole.1 |
Butoconazole nitrate |
Vaginal infection |
Do not list |
Complete |
June 30, 2004 |
January 26, 2005 |
SR0017-000 |
NovoMix 30 |
Insulin aspart/insulin aspart protamine |
Diabetes mellitus |
Do not list |
Complete |
October 13, 2005 |
April 26, 2006 |
SR0041-000 |
Fosavance 70/5600 |
Alendronate sodium / cholecalciferol |
Osteoporosis |
List in a similar manner to other drugs in class |
Complete |
December 18, 2008 |
June 17, 2009 |
SR0153-000 |
Abilify |
Aripiprazole |
Schizophrenia |
Do not list |
Complete |
November 6, 2009 |
April 27, 2010 |
SR0183-000 |
Abilify |
Aripiprazole |
Depression, Major Depressive Disorder |
Do not list |
Complete |
October 1, 2013 |
October 22, 2014 |
SR0354-000 |
Abilify |
Aripiprazole |
Schizophrenia and related psychotic disorders |
List with clinical criteria and/or conditions |
Complete |
March 29, 2011 |
July 18, 2011 |
SF0226-000 |
Abilify Maintena |
Aripiprazole |
Schizophrenia |
List with criteria/condition |
Complete |
January 6, 2014 |
December 19, 2014 |
SR0366-000 |
Abstral |
Fentanyl citrate |
Pain, breakthrough cancer pain |
Do not list |
Complete |
June 30, 2011 |
December 16, 2011 |
SR0240-000 |
Aclasta |
Zoledronic acid |
Osteoporosis |
List with clinical criteria and/or conditions |
Complete |
July 20, 2011 |
November 16, 2011 |
SF0242-000 |
Aclasta |
Zoledronic acid |
Osteoporosis, postmenopausal women |
List with clinical criteria and/or conditions |
Complete |
November 29, 2007 |
June 25, 2008 |
SR0114-000 |
Actemra |
Tocilizumab |
Arthritis, juvenile idiopathic |
List with clinical criteria and/or conditions |
Complete |
January 30, 2012 |
July 19, 2012 |
SR0267-000 |
Actemra |
Tocilizumab |
Arthritis, polyarticular juvenile idiopathic |
List with criteria/condition |
Complete |
July 29, 2013 |
March 19, 2014 |
SR0343-000 |
Actemra |
Tocilizumab |
Arthritis, rheumatoid |
List with criteria/condition |
Complete |
March 3, 2014 |
February 19, 2015 |
SR0374-000 |
Actemra |
Tocilizumab |
Arthritis, Rheumatoid |
List with clinical criteria and/or conditions |
Complete |
May 27, 2010 |
November 17, 2010 |
SR0201-000 |
Actemra |
tocilizumab |
Giant cell arteritis (GCA) |
Reimburse with clinical criteria and/or conditions |
Complete |
September 25, 2017 |
March 27, 2018 |
SR0534-000 |
Actikerall |
Fluorouracil and Salicylic Acid |
Hyperkeratotic actinic keratosis |
Reimburse with clinical criteria and/or conditions |
Complete |
August 31, 2016 |
March 22, 2017 |
SR0498-000 |
Adcirca |
Tadalafil |
Pulmonary arterial hypertension |
List with clinical criteria and/or conditions |
Complete |
February 5, 2010 |
July 15, 2010 |
SR0197-000 |
Adderall XR |
Mixed amphetamine salts |
Attention deficit hyperactivity disorder |
|
Withdrawn |
December 15, 2004 |
|
SR0027-000 |
Adderall XR |
Mixed amphetamine salts |
Attention deficit hyperactivity disorder |
Do not list |
Complete |
April 13, 2004 |
November 24, 2004 |
SR0010-000 |
Adderall XR |
Mixed amphetamine salts |
Attention deficit hyperactivity disorder, Adult |
Do not list |
Complete |
November 29, 2007 |
June 25, 2008 |
SR0116-000 |
Adempas |
Riociguat |
Chronic thromboembolic pulmonary hypertension |
List with criteria/condition |
Complete |
September 30, 2013 |
July 17, 2014 |
SR0353-000 |
Adempas |
Riociguat |
Pulmonary arterial hypertension (WHO group 1) |
List with clinical criteria and/or conditions |
Complete |
June 25, 2015 |
December 17, 2015 |
SR0438-000 |
Adlyxine |
lixisenatide |
Diabetes mellitus, Type 2 |
Reimburse with clinical criteria and/or conditions |
Complete |
May 29, 2017 |
November 23, 2017 |
SR0520-000 |
Admelog |
Insulin lispro |
|
|
Cancelled |
|
|
SE0543-000 |
Advicor |
Niacin/lovastatin |
Hypercholesterolemia and mixed dyslipidemia |
List |
Complete |
October 18, 2005 |
April 26, 2006 |
SR0042-000 |
Aermony RespiClick |
fluticasone propionate |
Asthma |
Reimburse with clinical criteria and/or conditions |
Complete |
October 4, 2017 |
December 19, 2018 |
SR0539-000 |
Zenhale (inhalation aerosol) |
Mometasone furoate and formoterol |
Asthma |
Do not list |
Complete |
February 16, 2011 |
September 28, 2011 |
SR0225-000 |
Afinitor |
Everolimus |
Subependymal giant cell astrocytoma associated with tuberous sclerosis complex |
Do not list |
Complete |
March 19, 2014 |
April 15, 2015 |
SR0376-000 |
Afinitor |
Everolimus |
Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) |
Do not list |
Complete |
March 8, 2013 |
September 25, 2013 |
SR0315-000 |
Aimovig |
erenumab |
Migraine |
Reimburse with clinical criteria and/or conditions |
Complete |
May 2, 2019 |
July 22, 2020 |
SR0578-000 |
Ajovy |
fremanezumab |
migraine |
|
Active |
June 3, 2020 |
|
SR0641-000 |
Akynzeo |
netupitant / palonosetron |
Nausea and vomiting (chemotherapy induced) prevention |
Reimburse with clinical criteria and/or conditions |
Complete |
December 8, 2017 |
June 20, 2018 |
SR0548-000 |
Aldurazyme |
Laronidase |
Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie |
Do not list |
Complete |
February 3, 2005 |
July 14, 2005 |
SR0032-000 |
Aloxi (capsule) |
Palonosetron |
Chemotherapy-induced nausea and vomiting |
|
Withdrawn |
February 6, 2015 |
|
SR0415-000 |
Aloxi (injection) |
Palonosetron hydrochloride |
Chemotherapy-induced nausea and vomiting |
Do not list at the submitted price |
Complete |
October 5, 2012 |
May 15, 2013 |
SR0293-000 |
Aloxi (capsule) |
Palonosetron hydrochloride |
Chemotherapy-induced nausea and vomiting |
Do not list |
Complete |
October 5, 2012 |
April 24, 2013 |
SR0294-000 |
Altace Plus Felodipine |
Ramipril/felodipine extended release |
Hypertension |
Do not list |
Complete |
June 22, 2006 |
November 15, 2006 |
SR0067-000 |
Altace HCT |
Ramipril/hydrochlorothiazide |
Hypertension |
|
Cancelled |
October 26, 2006 |
|
SR0083-000 |
Altace HCT |
Ramipril/hydrochlorothiazide |
Hypertension |
List |
Complete |
March 26, 2007 |
June 14, 2007 |
SR0095-000 |
Alvesco |
Ciclesonide |
asthma |
List |
Complete |
July 24, 2006 |
December 20, 2006 |
SR0074-000 |
Amevive |
Alefacept |
Psoriasis, moderate to severe chronic plaque |
Do not list |
Complete |
February 28, 2006 |
September 27, 2006 |
SR0053-000 |
Amevive |
Alefacept |
Psoriasis, moderate to severe chronic plaque |
Do not list |
Complete |
November 16, 2004 |
May 26, 2005 |
SR0024-000 |
Vocabria and Cabenuva |
cabotegravir sodium cabotegravir-rilpivirine |
HIV-1 infection |
Reimburse with clinical criteria and/or conditions |
Complete |
August 19, 2019 |
July 22, 2020 |
SR0628-000 |
Braftovi and Mektovi |
encorafenib and binimetinib |
Advanced Melanoma |
|
Active |
December 16, 2020 |
|
PC0232-000 |
Anoro Ellipta |
Umeclidinium/vilanterol |
Chronic obstructive pulmonary disease |
List with criteria/condition |
Complete |
February 26, 2014 |
January 15, 2015 |
SR0371-000 |
Apidra |
Insulin glulisine |
Diabetes, Mellitus (Type 1 & 2) |
List in a similar manner to other drugs in class |
Complete |
August 29, 2008 |
February 19, 2009 |
SR0144-000 |
Apprilon |
Doxycycline monohydrate |
Rosacea |
Do not list |
Complete |
April 27, 2012 |
March 27, 2013 |
SR0279-000 |
Aptiom |
Eslicarbazepine acetate |
Epilepsy, partial-onset seizures |
List with criteria/condition |
Complete |
August 15, 2014 |
April 16, 2015 |
SR0391-000 |
Aptivus |
Tipranavir |
HIV infection |
List with clinical criteria and/or conditions |
Complete |
December 15, 2005 |
May 17, 2006 |
SR0047-000 |
Arbesda RespiClick |
fluticasone propionate / salmeterol xinafoate |
Asthma |
Reimburse with clinical criteria and/or conditions |
Complete |
October 4, 2017 |
December 19, 2018 |
SR0540-000 |
Arnuity Ellipta |
Fluticasone furoate |
Asthma |
List with criteria/condition |
Complete |
June 26, 2015 |
December 17, 2015 |
SR0439-000 |
ASMANEX |
Mometasone furoate |
Asthma |
List |
Complete |
November 10, 2011 |
May 16, 2012 |
SR0258-000 |
Atectura Breezhaler |
indacaterol /mometasone furoate |
Asthma maintenance (adults, children 12 or older) |
Reimburse with clinical criteria and/or conditions |
Complete |
May 19, 2020 |
November 24, 2020 |
SR0646-000 |
Atripla |
Efavirenz, emtricitabine, tenofovir disoproxil fumarate |
HIV |
List with clinical criteria and/or conditions |
Complete |
October 30, 2007 |
April 17, 2008 |
SR0111-000 |
Aubagio |
Teriflunomide |
Multiple sclerosis, relapsing-remitting |
Do not list at the submitted price |
Complete |
August 28, 2013 |
June 18, 2014 |
SR0350-000 |
Somatuline Autogel |
Lanreotide acetate |
Acromegaly |
List in a similar manner to other drugs in class |
Complete |
February 20, 2007 |
July 19, 2007 |
SR0091-000 |
Avodart |
Dutasteride |
Prostatic hyperplasia, benign |
List in a similar manner to other drugs in class |
Complete |
August 24, 2004 |
January 20, 2005 |
SR0019-000 |
Axert |
Almotriptan |
Migraine |
List in a similar manner to other drugs in class |
Complete |
December 24, 2003 |
May 27, 2004 |
SR0005-000 |
Azarga |
Brinzolamide and timolol maleate suspension |
Glaucoma and ocular hypertension |
List in a similar manner to other drugs in class |
Complete |
August 28, 2009 |
February 18, 2010 |
SR0173-000 |
Azilect |
Rasagiline mesylate |
Parkinson's disease |
Do not list |
Complete |
September 1, 2006 |
March 28, 2007 |
SR0073-000 |
Azilect |
Rasagiline mesylate |
Parkinson?s disease |
|
Complete |
March 10, 2009 |
|
SF0161-000 |
Banzel |
Rufinamide |
Lennox-Gastaut syndrome |
List with clinical criteria and/or conditions |
Complete |
September 20, 2011 |
March 15, 2012 |
SR0252-000 |
Baqsimi |
glucagon |
Severe hypoglycemic reactions |
Reimburse with clinical criteria and/or conditions |
Complete |
July 24, 2019 |
January 22, 2020 |
SR0626-000 |
Baraclude |
Entecavir |
Hepatitis B (chronic) |
List with clinical criteria and/or conditions |
Complete |
December 12, 2006 |
November 28, 2007 |
SR0089-000 |
Basaglar |
Insulin glargine |
Diabetes mellitus, type 1; diabetes mellitus, type 2 |
List with clinical criteria and/or conditions |
Complete |
October 5, 2015 |
April 14, 2016 |
SE0451-000 |
Benlysta |
Belimumab |
systemic lupus erythematosus |
Do not reimburse |
Complete |
May 29, 2019 |
April 22, 2020 |
SR0616-000 |
Benlysta |
Belimumab |
Systemic lupus erythematosus |
Do not list |
Complete |
September 19, 2011 |
April 25, 2012 |
SR0251-000 |
Beovu |
brolucizumab |
Macular degeneration, age-related |
Reimburse with clinical criteria and/or conditions |
Complete |
September 26, 2019 |
May 21, 2020 |
SR0632-000 |
Biktarvy |
bictegravir/emtricitabine/tenofovir alafenamide |
HIV-1 infection |
Reimburse with clinical criteria and/or conditions |
Complete |
April 30, 2018 |
October 25, 2018 |
SR0567-000 |
Inflectra (Subsequent Entry Biologic) |
Infliximab |
Crohn’s disease and Ulcerative Colitis |
Reimburse with clinical criteria and/or conditions |
Complete |
April 12, 2016 |
October 25, 2016 |
SE0483-000 |
Botox |
OnabotulinumtoxinA |
Urinary incontinence |
List with criteria/condition |
Complete |
November 25, 2013 |
November 12, 2014 |
SR0362-000 |
Botox |
onabotulinumtoxinA |
Migraine, chronic |
Reimburse with clinical criteria and/or conditions |
Complete |
November 2, 2018 |
October 17, 2019 |
SR0584-000 |
Botox |
OnabotulinumtoxinA |
Neurogenic detrusor overactivity |
List with clinical criteria and/or conditions |
Complete |
January 31, 2012 |
July 19, 2012 |
SR0268-000 |
Botox |
OnabotulinumtoxinA |
Migraine |
Do not list |
Complete |
August 15, 2013 |
May 28, 2014 |
SR0345-000 |
Braftovi |
encorafenib |
Metastatic colorectal cancer |
|
Active |
December 16, 2020 |
|
PC0233-000 |
Ultibro Breezhaler |
Indacaterol/glycopyrronium |
Chronic obstructive pulmonary disease |
List with criteria/condition |
Complete |
February 3, 2014 |
December 19, 2014 |
SR0369-000 |
Enerzair Breezhaler |
indacaterol glycopyrronium mometasone furoate |
Asthma maintenance, adults |
Reimburse with clinical criteria and/or conditions |
Complete |
May 19, 2020 |
November 24, 2020 |
SR0645-000 |
Brenzys |
Etanercept |
Rheumatoid arthritis, Ankylosing spondylitis |
Reimburse with clinical criteria and/or conditions |
Complete |
April 20, 2016 |
October 25, 2016 |
SE0485-000 |
Breo Ellipta |
fluticasone furoate/vilanterol |
Asthma |
|
Withdrawn |
May 2, 2018 |
|
SR0568-000 |
Breo Ellipta |
Fluticasone Furoate and Vilanterol (as trifenatate) |
Asthma |
List with clinical criteria and/or conditions |
Complete |
August 10, 2015 |
February 18, 2016 |
SR0442-000 |
Breo Ellipta |
fluticasone furoate/vilanterol |
COPD |
|
Withdrawn |
June 28, 2017 |
|
SR0524-000 |
Breo Ellipta |
Fluticasone furoate /vilanterol |
Chronic Obstructive Pulmonary Disease (COPD) |
List with criteria/condition |
Complete |
October 29, 2013 |
August 18, 2014 |
SR0358-000 |
Brilinta |
ticagrelor |
Prevention of atherothrombotic events with history of myocardial infarction |
Reimburse with clinical criteria and/or conditions |
Complete |
February 18, 2016 |
August 25, 2016 |
SR0474-000 |
Brilinta |
Ticagrelor |
Acute coronary syndromes |
Do not list |
Complete |
June 1, 2011 |
December 16, 2011 |
SR0234-000 |
Brilinta |
Ticagrelor |
Acute Coronary Syndromes |
|
Cancelled |
June 8, 2010 |
|
SR0203-000 |
Brineura |
cerliponase alfa |
Neuronal Ceroid Lipofuscinosis Type 2 |
Reimburse with clinical criteria and/or conditions |
Complete |
July 31, 2018 |
May 23, 2019 |
SR0574-000 |
Brivlera |
Brivaracetam |
Epilepsy, partial-onset seizures |
Reimburse with clinical criteria and/or conditions |
Complete |
April 19, 2016 |
January 25, 2017 |
SR0484-000 |
BuTrans |
Buprenorphine transdermal patch |
Pain, moderate intensity persistent pain |
Do not list |
Complete |
May 9, 2011 |
September 28, 2011 |
SR0233-000 |
BuTrans |
Buprenorphine transdermal patch |
Pain, persistent (moderate intensity) |
|
Cancelled |
October 15, 2010 |
|
SR0211-000 |
Byetta |
Exenatide |
Diabetes mellitus, type 2 |
Do not list |
Complete |
August 23, 2011 |
July 19, 2012 |
SR0246-000 |
Bystolic |
Nebivolol |
Hypertension |
Do not list at the submitted price |
Complete |
February 4, 2013 |
July 18, 2013 |
SR0307-000 |
Cablivi |
caplacizumab |
Acquired thrombotic thrombocytopenic purpura (aTTP) |
Do not reimburse |
Complete |
September 13, 2019 |
August 26, 2020 |
SR0633-000 |
Caduet |
Amlodipine besylate/ atorvastatin calcium |
Hypertension/ Dyslipidemia |
List with clinical criteria and/or conditions |
Complete |
December 15, 2005 |
May 17, 2006 |
SR0048-000 |
Campral |
Acamprosate calcium |
Alcohol Abstinence |
|
Complete |
July 22, 2008 |
|
SF0143-000 |
Campral |
Acamprosate calcium |
Alcohol Abstinence |
List with clinical criteria and/or conditions |
Complete |
August 29, 2007 |
March 27, 2008 |
SR0108-000 |
Cayston |
Aztreonam for inhalation solution |
Cystic fibrosis, chronic pulmonary pseudomonas aeruginosa infections |
List with clinical criteria and/or conditions |
Complete |
December 2, 2010 |
July 18, 2011 |
SR0220-000 |
Celsentri |
Maraviroc |
HIV |
|
Withdrawn |
November 2, 2007 |
|
SR0113-000 |
Celsentri |
Maraviroc |
HIV |
List with clinical criteria and/or conditions |
Complete |
May 7, 2008 |
November 12, 2008 |
SR0136-000 |
Celsentri |
Maraviroc |
HIV infection |
Do not list |
Complete |
December 8, 2010 |
July 18, 2011 |
SR0221-000 |
Cerdelga |
Eliglustat |
Gaucher disease |
Reimburse with clinical criteria and/or conditions |
Complete |
January 20, 2017 |
July 26, 2017 |
SR0511-000 |
Champix |
Varenicline tartrate |
Smoking-cessation |
List with clinical criteria and/or conditions |
Complete |
March 21, 2007 |
August 16, 2007 |
SR0094-000 |
Cimzia |
Certolizumab pegol |
Arthritis, rheumatoid |
Do not list |
Complete |
September 3, 2009 |
May 27, 2010 |
SR0175-000 |
Cimzia |
Certolizumab pegol |
Arthritis, psoriatic |
List with criteria/condition |
Complete |
September 2, 2014 |
April 17, 2015 |
SR0394-000 |
Cimzia |
certolizumab pegol |
Psoriasis, moderate to severe plaque |
Reimburse with clinical criteria and/or conditions |
Complete |
May 13, 2019 |
November 20, 2019 |
SR0587-000 |
Cimzia |
Certolizumab pegol |
Ankylosing spondylitis |
List with criteria/condition |
Complete |
June 23, 2014 |
April 17, 2015 |
SR0385-000 |
Cinqair |
reslizumab |
Asthma, eosinophilic |
Reimburse with clinical criteria and/or conditions |
Complete |
October 24, 2018 |
March 27, 2019 |
SF0591-000 |
Cinqair |
Reslizumab |
Asthma, eosinophilic |
Reimburse with clinical criteria and/or conditions |
Complete |
August 4, 2016 |
March 22, 2017 |
SR0495-000 |
Cipralex |
Escitalopram oxalate |
Depression, Major Depressive Disorder (MDD) |
Do not list |
Complete |
June 8, 2006 |
January 24, 2007 |
SR0064-000 |
Cipralex |
Escitalopram oxalate |
Depression, Major Depressive Disorder (MDD) |
|
Withdrawn |
August 3, 2005 |
|
SR0039-000 |
Ciprodex |
Ciprofloxacin hydrochloride & dexamethasone otic suspension |
Otitis media with otorrhea & otitis externa, acute |
List with clinical criteria and/or conditions |
Complete |
June 15, 2007 |
October 18, 2007 |
SF0101-000 |
Ciprodex |
Ciprofloxacin hydrochloride and dexamethasone otic suspension |
Otitis media with otorrhea & otitis externa, acute |
Do not list |
Complete |
June 11, 2004 |
January 26, 2005 |
SR0014-000 |
Combigan Ophthalmic Solution |
Brimonidine tartrate/timolol maleate |
Glaucoma |
List with clinical criteria and/or conditions |
Complete |
December 15, 2003 |
May 27, 2004 |
SR0001-000 |
COMPLERA |
Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate |
HIV infection |
List |
Complete |
October 19, 2011 |
April 19, 2012 |
SR0256-000 |
Constella |
Linaclotide |
Irritable bowel syndrome with constipation |
Do not list |
Complete |
December 17, 2014 |
September 23, 2015 |
SR0409-000 |
Contrave |
naltrexone hydrochloride and bupropion hydrochloride |
Chronic weight management in adults |
Do not reimburse |
Complete |
May 1, 2019 |
May 27, 2020 |
SR0610-000 |
Copaxone |
Glatiramer acetate |
Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis |
Do not list |
Complete |
April 29, 2009 |
November 25, 2009 |
SR0164-000 |
Cortiment |
Budesonide |
Ulcerative Colitis |
Do not reimburse |
Complete |
May 24, 2016 |
March 22, 2017 |
SR0491-000 |
Corzyna |
ranolazine |
Stable angina pectoris, adults |
|
Active |
August 17, 2020 |
|
SR0655-000 |
Cosentyx |
Secukinumab |
Arthritis, psoriatic |
Reimburse with clinical criteria and/or conditions |
Complete |
February 19, 2016 |
August 23, 2016 |
SR0476-000 |
Cosentyx |
Secukinumab |
Plaque psoriasis |
List with criteria/condition |
Complete |
December 8, 2014 |
October 28, 2015 |
SR0407-000 |
Cosentyx |
Secukinumab |
ankylosing spondylitis |
Reimburse with clinical criteria and/or conditions |
Complete |
February 19, 2016 |
August 23, 2016 |
SR0475-000 |
Nucynta CR |
Tapentadol |
Pain, moderate to moderately severe |
Do not list |
Complete |
February 1, 2011 |
September 28, 2011 |
SR0224-000 |
Cresemba |
isavuconazole |
Treatment of invasive aspergillosis and mucormycosis |
Reimburse with clinical criteria and/or conditions |
Complete |
November 2, 2018 |
May 15, 2019 |
SR0586-000 |
Crysvita |
burosumab |
Treatment of X-Linked Hypophosphatemia |
Reimburse with clinical criteria and/or conditions |
Complete |
July 23, 2019 |
May 27, 2020 |
SR0602-000 |
Cubicin |
Daptomycin |
Skin and skin structure infections & bacteremia |
Do not list |
Complete |
March 6, 2008 |
September 24, 2008 |
SR0127-000 |
Cuvposa |
glycopyrrolate |
chronic severe drooling, neurologic (pediatric) |
Do not reimburse |
Complete |
May 31, 2019 |
June 24, 2020 |
SR0613-000 |
Cymbalta |
Duloxetine hydrochloride |
Depressive, Major Disorder (MDD) |
Do not list |
Complete |
February 8, 2008 |
August 14, 2008 |
SR0125-000 |
Cymbalta |
Duloxetine hydrochloride |
Pain, Neuropathic, Diabetic |
List with clinical criteria and/or conditions |
Complete |
February 8, 2008 |
August 14, 2008 |
SR0126-000 |
Cystadrops |
cysteamine |
Corneal cystine crystal deposits |
Reimburse with clinical criteria and/or conditions |
Complete |
December 10, 2018 |
June 18, 2019 |
SR0595-000 |
Daklinza |
daclatasvir |
Hepatitis C, Chronic |
Reimburse with clinical criteria and/or conditions |
Complete |
January 6, 2016 |
May 19, 2016 |
SF0467-000 |
Daklinza |
Daclatasvir |
Hepatitis C, Chronic |
List with clinical criteria and/or conditions |
Complete |
February 13, 2015 |
September 21, 2015 |
SR0417-000 |
Daxas |
Roflumilast |
Chronic obstructive pulmonary disease |
Do not list |
Complete |
November 30, 2010 |
July 27, 2011 |
SR0218-000 |
Delstrigo |
doravirine lamuvidine tenofovir disoproxil fumarate |
HIV-1 infection |
Reimburse with clinical criteria and/or conditions |
Complete |
November 16, 2018 |
May 14, 2019 |
SR0581-000 |
Denavir |
Penciclovir |
Herpes labialis (cold sores) |
Do not list |
Complete |
September 20, 2006 |
April 26, 2007 |
SR0075-000 |
Descovy |
Emtricitabine /tenofovir alafenamide |
HIV-1 infection |
Reimburse with clinical criteria and/or conditions |
Complete |
January 29, 2016 |
August 24, 2016 |
SR0470-000 |
Diacomit |
Stiripentol |
Dravet Syndrome |
List with criteria/condition |
Complete |
October 30, 2013 |
October 16, 2014 |
SR0360-000 |
Dificid |
Fidaxomicin |
Clostridium difficile infection |
Do not list at the submitted price |
Complete |
July 10, 2012 |
December 19, 2012 |
SR0285-000 |
Dovato |
dolutegravir / lamivudine |
HIV-1 infection |
Reimburse with clinical criteria and/or conditions |
Complete |
February 21, 2019 |
September 30, 2019 |
SR0601-000 |
Duaklir Genuair |
Aclidinium bromide/formoterol fumarate dihydrate |
Chronic obstructive pulmonary disease |
List with clinical criteria and/or conditions |
Complete |
April 1, 2015 |
September 18, 2015 |
SR0423-000 |
Duobrii |
Halobetasol propionate and tazarotene |
Psoriasis, moderate to severe plaque |
Reimburse with clinical criteria and/or conditions |
Complete |
January 24, 2020 |
October 28, 2020 |
SR0638-000 |
Duodopa |
Levodopa / carbidopa (Drug Plan Submission) |
Parkinson's disease |
Reimburse with clinical criteria and/or conditions |
Complete |
February 8, 2018 |
August 22, 2018 |
SR0557-000 |
Duodopa |
Levodopa / carbidopa |
Parkinson's disease |
Do not list |
Complete |
December 19, 2008 |
July 22, 2009 |
SR0154-000 |
DuoTrav |
Travoprost and timolol maleate |
Glaucoma |
List with clinical criteria and/or conditions |
Complete |
March 24, 2006 |
August 24, 2006 |
SR0057-000 |
Dupixent |
dupilumab |
atopic dermatitis |
Do not reimburse |
Complete |
October 27, 2017 |
June 27, 2018 |
SR0533-000 |
Dupixent |
dupilumab |
atopic dermatitis |
Reimburse with clinical criteria and/or conditions |
Complete |
October 22, 2019 |
April 22, 2020 |
SR0636-000 |
Dupixent |
dupilumab |
Asthma |
|
Active |
November 26, 2020 |
|
SR0667-000 |
Dymista |
Azelastine HCl and fluticasone propionate |
Seasonal allergic rhinitis |
Do not list |
Complete |
December 9, 2014 |
June 17, 2015 |
SR0408-000 |
Dysport Therapeutic |
abobotulinumtoxinA |
lower limb spasticity |
Reimburse with clinical criteria and/or conditions |
Complete |
February 7, 2018 |
August 23, 2018 |
SR0556-000 |
Dysport Therapeutic |
abobotulinumtoxinA |
Upper limb spasticity |
Reimburse with clinical criteria and/or conditions |
Complete |
April 24, 2017 |
October 24, 2017 |
SR0517-000 |
Dysport Therapeutic |
abobotulinumtoxinA |
Cervical dystonia |
Reimburse with clinical criteria and/or conditions |
Complete |
January 31, 2017 |
July 26, 2017 |
SR0512-000 |
Ebixa |
Memantine hydrochloride |
Dementia (Alzheimer type), moderate to severe |
Do not list |
Complete |
December 21, 2004 |
November 23, 2005 |
SR0025-000 |
Edarbi |
Azilsartan medoxomil |
Hypertension |
Do not list at the submitted price |
Complete |
March 8, 2013 |
October 17, 2013 |
SR0317-000 |
Edarbyclor |
Azilsartan medoxomil + chlorthalidone |
Hypertension |
Do not list |
Complete |
March 8, 2013 |
October 17, 2013 |
SR0318-000 |
Edurant |
Rilpivirine |
HIV infection |
List |
Complete |
July 29, 2011 |
February 15, 2012 |
SR0243-000 |
Effient |
Prasugrel |
Acute coronary syndrome |
Do not list |
Complete |
December 12, 2011 |
June 14, 2012 |
SR0263-000 |
Effient |
Prasugrel hydrochloride |
Acute Coronary Syndrome |
Do not list |
Complete |
May 5, 2010 |
February 16, 2011 |
SR0200-000 |
Egrifta |
Tesamorelin |
Lipodystrophy, HIV-infected patients |
Do not reimburse |
Complete |
March 2, 2016 |
August 24, 2016 |
SR0477-000 |
Elaprase |
Idursulfase |
Mucopolysarccharidosis II (MPS II), Hunter Syndrome |
Do not list |
Complete |
July 13, 2007 |
December 19, 2007 |
SR0104-000 |
Elelyso |
Taliglucerase alfa |
Gaucher disease |
Do not list |
Complete |
August 15, 2014 |
October 28, 2015 |
SR0390-000 |
Eliquis |
Apixaban |
Thromboembolic events prevention, (atrial fibrillation) |
List with clinical criteria and/or conditions |
Complete |
September 25, 2012 |
March 20, 2013 |
SR0288-000 |
Eliquis |
Apixaban |
Venous thromboembolic events, prevention |
List with clinical criteria and/or conditions |
Complete |
December 20, 2011 |
June 14, 2012 |
SR0264-000 |
Eliquis |
Apixaban |
Venous thromboembolic events, treatment and prevention of recurrence |
List with clinical criteria and/or conditions |
Complete |
September 18, 2014 |
May 7, 2015 |
SR0397-000 |
Trelegy Ellipta |
fluticasone furoate umeclidinium vilanterol |
Chronic obstructive pulmonary disease (COPD) |
Reimburse with clinical criteria and/or conditions |
Complete |
March 1, 2018 |
August 23, 2018 |
SR0562-000 |
Incruse Ellipta |
Umeclidinium |
Chronic obstructive pulmonary disease |
List with criteria/condition |
Complete |
March 4, 2015 |
September 18, 2015 |
SR0422-000 |
Emend |
Aprepitant |
Nausea and Vomiting, Chemotherapy induced |
List with clinical criteria and/or conditions |
Complete |
August 29, 2007 |
February 20, 2008 |
SR0109-000 |
Restasis ophthalmic emulsion |
Cyclosporine |
Dry eye disease |
Do not list |
Complete |
December 17, 2010 |
July 18, 2011 |
SR0222-000 |
Enablex |
Darifenacin hydrobromide |
Bladder, overactive |
List with clinical criteria and/or conditions |
Complete |
October 1, 2008 |
April 16, 2009 |
SR0147-000 |
Enablex |
Darifenacin hydrobromide |
Bladder, overactive |
Do not list |
Complete |
April 26, 2006 |
October 19, 2006 |
SR0061-000 |
Enspryng |
satralizumab |
Neuromyelitis optica spectrum disorder |
|
Active |
October 22, 2020 |
|
SR0663-000 |
Entresto |
Sacubitril/valsartan |
Heart failure, NYHA class II or III |
List with clinical criteria and/or conditions |
Complete |
September 18, 2015 |
March 18, 2016 |
SR0447-000 |
Entresto |
sacubitril/valsartan |
Heart failure, NYHA Class II or III |
|
Active |
May 22, 2020 |
|
SR0644-000 |
Entuzity KwikPen |
human insulin |
Diabetes mellitus |
|
Active |
January 27, 2021 |
|
SR0672-000 |
Entyvio |
vedolizumab |
Crohn’s disease |
|
Active |
July 23, 2020 |
January 21, 2021 |
SR0647-000 |
Entyvio |
Vedolizumab |
Ulcerative colitis |
List with clinical criteria and/or conditions |
Complete |
February 20, 2015 |
October 28, 2015 |
SR0421-000 |
Entyvio |
Vedolizumab |
Crohn's disease |
Reimburse with clinical criteria and/or conditions |
Complete |
April 27, 2016 |
October 31, 2016 |
SR0487-000 |
Entyvio |
vedolizumab |
Ulcerative Colitis |
Reimburse with clinical criteria and/or conditions |
Complete |
November 21, 2019 |
May 19, 2020 |
SR0635-000 |
Epclusa |
Sofosbuvir/ velpatasvir |
Hepatitis C, chronic |
Reimburse with clinical criteria and/or conditions |
Complete |
April 22, 2016 |
October 26, 2016 |
SR0486-000 |
Erelzi |
Etanercept |
Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis |
Reimburse with clinical criteria and/or conditions |
Complete |
February 2, 2017 |
July 25, 2017 |
SE0513-000 |
Esbriet |
Pirfenidone |
Idiopathic pulmonary fibrosis |
Do not list |
Complete |
October 5, 2012 |
April 18, 2013 |
SR0292-000 |
Esbriet |
Pirfenidone |
Idiopathic pulmonary fibrosis |
List with criteria/condition |
Complete |
August 29, 2014 |
April 15, 2015 |
SR0393-000 |
Eucrisa |
crisaborole |
atopic dermatitis |
Do not reimburse |
Complete |
May 25, 2018 |
March 27, 2019 |
SR0570-000 |
Evenity |
romosozumab |
Osteoporosis, postmenopausal women |
|
Active |
February 1, 2021 |
|
SR0676-000 |
Evra |
Norgelestromin/ethinyl estradiol |
Contraceptive, patch |
Do not list |
Complete |
December 19, 2003 |
June 23, 2004 |
SR0004-000 |
Exelon Patch |
Rivastigmine |
Dementia (Alzheimer's type) |
Do not list |
Complete |
December 21, 2007 |
July 23, 2008 |
SR0123-000 |
Exjade |
Deferasirox |
Iron overload |
List with clinical criteria and/or conditions |
Complete |
October 26, 2006 |
April 19, 2007 |
SR0081-000 |
Eylea |
Aflibercept |
Macular edema, diabetic |
List with clinical criteria and/or conditions |
Complete |
September 16, 2014 |
May 7, 2015 |
SR0396-000 |
Eylea |
Aflibercept |
Macular edema, central retinal vein occlusion |
List with clinical criteria and/or conditions |
Complete |
October 17, 2014 |
May 7, 2015 |
SR0401-000 |
Eylea |
Aflibercept |
Macular degeneration, age-related |
List with criteria/condition |
Complete |
November 18, 2013 |
October 20, 2014 |
SR0361-000 |
Eylea |
Aflibercept |
Macular edema, branch retinal vein occlusion |
Reimburse with clinical criteria and/or conditions |
Complete |
December 14, 2015 |
July 27, 2016 |
SR0460-000 |
Fabrazyme |
Agalsidase beta |
Fabry Disease |
Do not list |
Complete |
February 24, 2004 |
November 24, 2004 |
SR0007-000 |
Fabrazyme |
Agalsidase beta |
Fabry Disease |
Do not list |
Complete |
December 10, 2004 |
May 18, 2005 |
SR0028-000 |
Fampyra |
Fampridine |
Multiple sclerosis, improve walking disability |
Do not list |
Complete |
April 16, 2012 |
November 28, 2012 |
SR0275-000 |
Fampyra |
Fampridine |
Multiple sclerosis, improve walking disability |
|
Withdrawn |
November 6, 2014 |
|
SR0404-000 |
Fasenra |
benralizumab |
Asthma, severe eosinophilic |
Reimburse with clinical criteria and/or conditions |
Complete |
October 24, 2018 |
March 27, 2019 |
SF0592-000 |
Fasenra |
benralizumab |
Asthma, severe eosinophilic |
Reimburse with clinical criteria and/or conditions |
Complete |
February 23, 2018 |
August 21, 2018 |
SR0561-000 |
Fentora |
Fentanyl buccal |
Pain (breakthrough), cancer (adults) |
Do not reimburse |
Complete |
July 12, 2016 |
February 21, 2017 |
SR0494-000 |
Ferriprox |
Deferiprone |
Transfusional iron overload |
List with clinical criteria and/or conditions |
Complete |
September 24, 2015 |
March 18, 2016 |
SR0448-000 |
Fibristal |
ulipristal acetate |
Uterine fibroids (signs and symptoms) |
Reimburse with clinical criteria and/or conditions |
Complete |
March 28, 2019 |
July 24, 2019 |
SF0609-000 |
Fibristal |
ulipristal acetate |
Uterine fibroids (signs and symptoms) |
Reimburse with clinical criteria and/or conditions |
Complete |
June 21, 2017 |
November 22, 2017 |
SF0528-000 |
Fibristal |
Ulipristal acetate |
Uterine fibroids |
List with criteria/condition |
Complete |
April 17, 2013 |
November 15, 2013 |
SR0326-000 |
Finacea |
Azelaic acid |
Rosacea |
List |
Complete |
August 31, 2010 |
February 16, 2011 |
SR0209-000 |
Firazyr |
Icatibant |
Hereditary angioedema |
List with clinical criteria and/or conditions |
Complete |
March 4, 2014 |
December 19, 2014 |
SR0375-000 |
Firazyr |
icatibant |
|
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer |
NotFiled |
|
|
|
Forteo |
Teriparatide (rDNA origin) injection |
Osteoporosis (in women), Severe |
Do not list |
Complete |
October 23, 2009 |
March 17, 2010 |
SR0180-000 |
Forteo |
Teriparatide (rDNA origin) injection |
Osteoporosis, glucocorticoid induced |
Do not list |
Complete |
December 18, 2008 |
July 22, 2009 |
SR0152-000 |
Forteo |
Teriparatide (rDNA origin) injection |
Osteoporosis |
Do not list |
Complete |
June 8, 2004 |
December 22, 2004 |
SR0015-000 |
Forteo |
Teriparatide (rDNA origin) injection |
Osteoporosis |
|
Withdrawn |
May 29, 2006 |
|
SR0065-000 |
Forteo |
Teriparatide (rDNA origin) injection |
Osteoporosis |
|
Withdrawn |
June 12, 2009 |
|
SR0169-000 |
Forteo |
Teriparatide (rDNA origin) injection |
Osteoporosis |
|
Withdrawn |
December 18, 2008 |
|
SR0157-000 |
Forxiga |
Dapagliflozin |
Diabetes mellitus, type 2 |
Do not list |
Complete |
September 4, 2015 |
April 27, 2016 |
SR0445-000 |
Forxiga |
dapagliflozin |
Heart failure with reduced ejection fraction |
Reimburse with clinical criteria and/or conditions |
Active |
March 31, 2020 |
December 23, 2020 |
SR0642-000 |
Forxiga |
Dapagliflozin |
Diabetes mellitus, type 2 |
List with clinical criteria and/or conditions |
Complete |
April 30, 2015 |
November 20, 2015 |
SR0428-000 |
Fosavance |
Alendronate sodium/cholecalciferol |
Osteoporosis |
Do not list |
Complete |
March 27, 2006 |
September 27, 2006 |
SR0059-000 |
Fosrenol |
Lanthanum carbonate hydrate |
Hyperphosphatemia, end-stage renal disease |
Do not list |
Complete |
June 28, 2007 |
January 30, 2008 |
SR0100-000 |
Fulphila |
pegfilgrastim |
Febrile neutropenia in non-myeloid malignancies |
|
Complete |
November 14, 2018 |
|
SE0588-000 |
Fycompa |
Perampanel |
Epilepsy, partial onset seizures |
List with criteria/condition |
Complete |
March 8, 2013 |
October 17, 2013 |
SR0316-000 |
Fycompa |
Perampanel |
Epilepsy, primary generalized tonic-clonic seizures |
Reimburse with clinical criteria and/or conditions |
Complete |
November 24, 2015 |
May 18, 2016 |
SR0458-000 |
Galafold |
migalastat |
Fabry Disease |
Reimburse with clinical criteria and/or conditions |
Complete |
June 9, 2017 |
January 24, 2018 |
SR0522-000 |
Galexos |
Simeprevir |
Hepatitis C, chronic |
List with criteria/condition |
Complete |
August 22, 2013 |
June 18, 2014 |
SR0347-000 |
Gelnique |
Oxybutynin Chloride Gel |
Overactive bladder |
Do not list |
Complete |
October 25, 2011 |
May 24, 2012 |
SR0260-000 |
Genotropin |
Somatropin |
Growth hormone deficiency, adult |
List with criteria/condition |
Complete |
May 27, 2013 |
December 20, 2013 |
SR0332-000 |
Genotropin |
Somatropin |
Growth hormone deficiency, children |
List with criteria/condition |
Complete |
May 27, 2013 |
December 20, 2013 |
SR0333-000 |
Genotropin |
Somatropin |
Turner Syndrome |
List with criteria/condition |
Complete |
May 27, 2013 |
December 20, 2013 |
SR0334-000 |
Tudorza Genuair |
Aclidinium bromide |
Chronic Obstructive Pulmonary Disease |
List with criteria/condition |
Complete |
August 21, 2013 |
April 21, 2014 |
SR0346-000 |
Genvoya |
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide |
HIV infection |
List |
Complete |
September 24, 2015 |
March 18, 2016 |
SR0449-000 |
Gilenya |
Fingolimod |
Multiple Sclerosis, relapsing-remitting |
List with clinical criteria and/or conditions |
Complete |
May 10, 2011 |
November 16, 2011 |
SR0228-000 |
Givlaari |
givosiran |
Acute hepatic porphyria (AHP) in adults |
|
Received |
February 23, 2021 |
|
SR0679-000 |
Glatect |
Glatiramer acetate |
Relapsing Remitting Multiple Sclerosis (RRMS) |
Reimburse with clinical criteria and/or conditions |
Complete |
January 20, 2017 |
July 25, 2017 |
SE0510-000 |
Grastek |
Phleum pratense |
Allergic rhinitis |
Do not list |
Complete |
September 30, 2013 |
September 24, 2014 |
SR0352-000 |
Grastofil |
Filgrastim |
Neutropenia |
List with clinical criteria and/or conditions |
Complete |
September 11, 2015 |
March 18, 2016 |
SE0446-000 |
Harvoni |
Ledipasvir / Sofosbuvir |
Hepatitis C, chronic |
List with criteria/condition |
Complete |
September 15, 2014 |
March 18, 2015 |
SR0395-000 |
Harvoni |
ledipasvir, sofosbuvir |
Hepatitis C, chronic |
Reimburse with clinical criteria and/or conditions |
Complete |
January 6, 2016 |
May 18, 2016 |
SF0465-000 |
Hemangiol |
Propranolol oral solution |
Infantile hemangioma |
Reimburse with clinical criteria and/or conditions |
Complete |
August 25, 2016 |
February 21, 2017 |
SR0496-000 |
Hemangiol |
Propranolol |
Infantile hemangioma |
|
Withdrawn |
December 23, 2014 |
|
SR0411-000 |
Hemlibra |
emicizumab |
Bleeding prevention, hemophilia A |
Reimburse with clinical criteria and/or conditions |
Complete |
June 30, 2020 |
December 21, 2020 |
ST0651-000 |
Hepsera |
Adefovir dipivoxil |
Hepatitis B |
List with clinical criteria and/or conditions |
Complete |
June 29, 2007 |
October 18, 2007 |
SF0103-000 |
Hepsera |
Adefovir dipivoxil |
Hepatitis B |
Do not list |
Complete |
April 24, 2006 |
November 29, 2006 |
SR0060-000 |
Holkira Pak |
ombitasvir/paritaprevir/ritonavir and dasabuvir |
Hepatitis C, chronic |
Reimburse with clinical criteria and/or conditions |
Complete |
January 6, 2016 |
May 19, 2016 |
SF0466-000 |
Holkira Pak |
Ombitasvir/paritaprevir/ritonavir and dasabuvir |
Hepatitis C, chronic |
List with clinical criteria and/or conditions |
Complete |
December 3, 2014 |
June 18, 2015 |
SR0406-000 |
Humira |
Adalimumab |
Crohn's disease |
List with clinical criteria and/or conditions |
Complete |
July 12, 2007 |
December 19, 2007 |
SR0105-000 |
Humira |
Adalimumab |
Arthritis, Rheumatoid |
List with clinical criteria and/or conditions |
Complete |
September 24, 2004 |
February 11, 2005 |
SR0022-000 |
Humira |
Adalimumab |
Arthritis, juvenile idiopathic |
List with clinical criteria and/or conditions |
Complete |
February 4, 2013 |
July 18, 2013 |
SR0308-000 |
Humira |
Adalimumab |
Ankylosing spondylitis (AS) |
List with clinical criteria and/or conditions |
Complete |
November 17, 2006 |
June 27, 2007 |
SR0087-000 |
Humira |
Adalimumab |
Ulcerative colitis |
Do not list at the submitted price |
Complete |
September 25, 2015 |
April 15, 2016 |
SR0450-000 |
Humira |
Adalimumab |
ulcerative colitis |
|
Withdrawn |
December 23, 2013 |
|
SR0365-000 |
Humira |
Adalimumab |
Psoriasis |
List with clinical criteria and/or conditions |
Complete |
April 15, 2008 |
October 16, 2008 |
SR0130-000 |
Humira |
Adalimumab |
Arthritis, Psoriatic |
List with clinical criteria and/or conditions |
Complete |
June 21, 2006 |
November 29, 2006 |
SR0066-000 |
Humira |
Adalimumab |
Hidradenitis suppurativa |
Reimburse with clinical criteria and/or conditions |
Complete |
November 3, 2015 |
May 19, 2016 |
SR0455-000 |
Simponi I.V. |
Golimumab |
Arthritis, rheumatoid |
List with criteria/condition |
Complete |
September 12, 2013 |
July 17, 2014 |
SR0351-000 |
Stelara/Stelara I.V |
ustekinumab |
Ulcerative colitis |
Reimburse with clinical criteria and/or conditions |
Complete |
August 12, 2019 |
July 16, 2020 |
SR0627-000 |
Stelara/Stelara I.V. |
ustekinumab |
Crohn’s disease |
Reimburse with clinical criteria and/or conditions |
Complete |
September 12, 2016 |
March 21, 2017 |
SR0501-000 |
Ikervis |
cyclosporine |
keratitis, severe |
|
Withdrawn |
May 15, 2017 |
|
SR0518-000 |
Ilaris |
Canakinumab |
Cryopyrin-Associated Periodic Syndrome |
Do not list |
Complete |
July 7, 2010 |
January 26, 2011 |
SR0204-000 |
Ilaris |
Canakinumab |
Systemic Juvenile Idiopathic Arthritis |
Reimburse with clinical criteria and/or conditions |
Complete |
December 23, 2015 |
June 17, 2016 |
SR0463-000 |
Ilumya |
tildrakizumab |
Psoriasis, moderate to severe plaque |
|
Active |
July 15, 2019 |
|
SR0624-000 |
Iluvien |
fluocinolone acetonide |
Diabetic macular edema (DME) |
|
Withdrawn |
December 21, 2017 |
|
SR0549-000 |
Iluvien |
fluocinolone acetonide intravitreal implant |
diabetic macular edema |
Do not reimburse |
Complete |
April 3, 2019 |
September 26, 2019 |
SR0608-000 |
Imbruvica |
ibrutinib |
|
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer |
NotFiled |
|
|
|
Imfinzi |
durvalumab |
Extensive-stage small cell lung cancer |
|
Active |
December 1, 2020 |
|
PC0234-000 |
Incivek |
Telaprevir |
Hepatitis C, chronic |
List with clinical criteria and/or conditions |
Complete |
August 23, 2011 |
February 15, 2012 |
SR0249-000 |
Incivek |
Telaprevir |
Hepatitis C, chronic |
List with criteria/condition |
Complete |
February 19, 2013 |
June 13, 2013 |
SF0311-000 |
Incivek |
Telaprevir |
Hepatitis C, chronic |
List with criteria/condition |
Complete |
December 21, 2012 |
June 13, 2013 |
SF0305-000 |
Inflectra |
Infliximab |
Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis |
List with criteria/condition |
Complete |
June 17, 2014 |
December 19, 2014 |
SE0384-000 |
Inrebic |
fedratinib |
Myelofibrosis |
|
Active |
November 5, 2020 |
|
PC0205-000 |
Inspiolto Respimat |
Tiotropium / olodaterol |
|
List with criteria/condition |
Complete |
June 4, 2015 |
December 17, 2015 |
SR0436-000 |
Inspra |
Eplerenone |
Heart failure, NYHA class II |
Do not list at the submitted price |
Complete |
July 12, 2013 |
April 24, 2014 |
SR0342-000 |
Inspra |
Eplerenone |
Post myocardial infarction |
Do not list |
Complete |
May 6, 2009 |
November 25, 2009 |
SR0165-000 |
Intelence |
Etravirine |
HIV |
List with clinical criteria and/or conditions |
Complete |
April 2, 2008 |
August 14, 2008 |
SR0129-000 |
Intuniv XR |
Guanfacine hydrochloride |
Attention-deficit/hyperactivity disorder (ADHD) |
Do not list |
Complete |
August 27, 2013 |
September 24, 2014 |
SR0349-000 |
Invega |
Paliperidone |
Schizophrenia |
Do not list |
Complete |
November 1, 2007 |
May 28, 2008 |
SR0112-000 |
Invega Sustenna |
Paliperidone palmitate |
Schizophrenia |
Do not list |
Complete |
July 9, 2010 |
April 25, 2011 |
SR0206-000 |
Invokamet |
Canagliflozin and metformin hydrochloride |
diabetes mellitus, type 2 |
Reimburse with clinical criteria and/or conditions |
Complete |
March 3, 2016 |
August 25, 2016 |
SR0480-000 |
Invokana |
Canagliflozin |
Diabetes Mellitus, Type 2 |
|
Withdrawn |
June 5, 2013 |
|
SR0335-000 |
Invokana |
Canagliflozin |
Diabetes mellitus, type 2 |
List with criteria/condition |
Complete |
February 24, 2014 |
January 15, 2015 |
SR0370-000 |
Iressa |
Gefitinib |
Cancer, Lung , non-small cell |
Do not list |
Complete |
December 22, 2003 |
June 23, 2004 |
SR0003-000 |
Isentress |
Raltegravir |
HIV |
List with clinical criteria and/or conditions |
Complete |
November 29, 2007 |
May 14, 2008 |
SR0115-000 |
Isentress |
Raltegravir |
HIV (treatment naïve) |
Do not list |
Complete |
December 4, 2009 |
June 23, 2010 |
SR0191-000 |
Izba |
travoprost ophthalmic solution |
Glaucoma and ocular hypertension |
Reimburse with clinical criteria and/or conditions |
Complete |
March 1, 2017 |
October 25, 2017 |
SR0516-000 |
Janumet |
Sitagliptin phosphate monohydrate / metformin hydrochloride |
Diabetes mellitus (Type 2) |
List with clinical criteria and/or conditions |
Complete |
November 4, 2009 |
June 23, 2010 |
SR0182-000 |
Januvia |
Sitagliptin phosphate |
Diabetes mellitus (Type 2) |
Do not list |
Complete |
December 20, 2007 |
June 18, 2008 |
SR0122-000 |
Januvia |
Sitagliptin phosphate |
Diabetes mellitus (Type 2) |
List with clinical criteria and/or conditions |
Complete |
October 29, 2009 |
June 23, 2010 |
SR0181-000 |
Jardiance |
Empagliflozin |
Diabetes mellitus, type 2 with high cardiovascular risk |
Reimburse with clinical criteria and/or conditions |
Complete |
April 27, 2016 |
October 26, 2016 |
SR0488-000 |
Jardiance |
Empagliflozin |
Diabetes mellitus, type 2 |
List with clinical criteria and/or conditions |
Complete |
April 23, 2015 |
October 15, 2015 |
SR0427-000 |
Jentadueto |
Linagliptin-metformin |
Diabetes mellitus, type 2 |
List with criteria/condition |
Complete |
March 8, 2013 |
October 17, 2013 |
SR0306-000 |
Jetrea |
Ocriplasmin |
Vitreomacular adhesion |
List with criteria/condition |
Complete |
June 6, 2013 |
December 20, 2013 |
SR0337-000 |
Jinarc |
Tolvaptan |
Autosomal dominant polycystic kidney disease |
Do not list |
Complete |
May 29, 2015 |
February 24, 2016 |
SR0435-000 |
Jorveza |
budesonide |
Eosinophilic esophagitis, adults |
Reimburse with clinical criteria and/or conditions |
Complete |
November 8, 2019 |
October 28, 2020 |
SR0634-000 |
Jorveza |
budesonide |
Maintenance of Eosinophilic esophagitis in adults |
|
Active |
November 5, 2020 |
|
SR0666-000 |
Jublia |
efinaconazole |
Onychomycosis |
Do not reimburse |
Complete |
August 2, 2018 |
May 23, 2019 |
SR0577-000 |
Juluca |
Dolutegravir rilpivirine |
HIV infection |
Reimburse with clinical criteria and/or conditions |
Complete |
December 21, 2017 |
June 20, 2018 |
SR0551-000 |
Jurnista |
Hydromorphone hydrochloride |
Pain, Chronic (moderate to severe) |
Do not list |
Complete |
December 4, 2009 |
May 19, 2010 |
SR0190-000 |
Juxtapid |
Lomitapide |
Hypercholesterolemia, homozygous familial |
Do not list |
Complete |
July 8, 2014 |
April 17, 2015 |
SR0386-000 |
Kalydeco |
Ivacaftor |
Cystic Fibrosis, CFTR gating mutations |
List with criteria/condition |
Complete |
May 1, 2014 |
December 19, 2014 |
SR0379-000 |
Kalydeco |
Ivacaftor |
Cystic fibrosis, R117H CFTR gating mutation |
List with criteria/condition |
Complete |
May 8, 2015 |
November 19, 2015 |
SR0430-000 |
Kalydeco |
Ivacaftor |
Cystic fibrosis, G551D mutation |
List with criteria/condition |
Complete |
September 27, 2012 |
March 22, 2013 |
SR0291-000 |
Kanuma |
sebelipase alfa |
Lysosomal acid lipase deficiency |
Reimburse with clinical criteria and/or conditions |
Complete |
November 2, 2017 |
September 26, 2018 |
SR0544-000 |
Kazano |
Alogliptin plus metformin |
Diabetes mellitus, type 2 |
Do not list |
Complete |
January 30, 2014 |
January 15, 2015 |
SR0367-000 |
Kesimpta |
ofatumumab |
Multiple Sclerosis, relapsing |
|
Active |
August 25, 2020 |
|
SR0657-000 |
Kevzara |
sarilumab |
Arthritis, Rheumatoid |
Reimburse with clinical criteria and/or conditions |
Complete |
October 12, 2016 |
April 18, 2017 |
SR0503-000 |
Keytruda |
pembrolizumab |
Colorectal cancer |
|
Active |
November 30, 2020 |
|
PC0235-000 |
Keytruda |
pembrolizumab |
Classical Hodgkin lymphoma |
|
Received |
January 29, 2021 |
|
PC0236-000 |
Kineret |
anakinra |
Still's disease |
|
Active |
December 21, 2020 |
|
SR0662-000 |
Kivexa |
Abacavir/lamivudine |
HIV infection |
List in a similar manner to other drugs in class |
Complete |
July 26, 2005 |
December 7, 2005 |
SR0038-000 |
Komboglyze |
Saxagliptin + metformin |
Diabetes Mellitus, Type 2 |
|
Withdrawn |
June 6, 2013 |
|
SR0336-000 |
Komboglyze |
Saxagliptin + metformin |
Diabetes Mellitus, type 2 |
List with criteria/condition |
Complete |
August 23, 2013 |
June 20, 2014 |
SR0348-000 |
Kuvan |
Sapropterin dihydrochloride |
Phenylketonuria (PKU) |
Reimburse with clinical criteria and/or conditions |
Complete |
February 1, 2016 |
October 26, 2016 |
SR0472-000 |
Kuvan |
Sapropterin dihydrochloride |
Phenylketonuria (PKU) |
Do not list |
Complete |
July 8, 2010 |
January 26, 2011 |
SR0205-000 |
Kuvan |
Sapropterin dihydrochloride |
Phenylketonuria |
|
Complete |
June 1, 2011 |
|
SF0236-000 |
Kynmobi |
apomorphine hydrochloride |
Parkinson’s disease |
Reimburse with clinical criteria and/or conditions |
Active |
June 25, 2020 |
February 24, 2021 |
SR0650-000 |
Kynmobi |
apomorphine hydrochloride |
Parkinson’s Disease |
|
Withdrawn |
February 25, 2019 |
|
SR0604-000 |
Lancora |
Ivabradine |
Heart failure, NYHA class II or III |
Reimburse with clinical criteria and/or conditions |
Complete |
November 8, 2016 |
May 24, 2017 |
SR0506-000 |
Lantus |
Insulin glargine (rDNA origin) |
Diabetes mellitus, Type 1 & 2 |
|
Complete |
June 9, 2009 |
|
SF0166-000 |
Lantus |
Insulin glargine (rDNA origin) |
Diabetes mellitus, Type 1 & 2 |
Do not list |
Complete |
February 11, 2005 |
September 28, 2005 |
SR0033-000 |
Lantus |
Insulin glargine (rDNA origin) |
Diabetes mellitus, Type 1 & 2 |
Do not list |
Complete |
March 27, 2006 |
October 25, 2006 |
SR0058-000 |
Lapelga |
Pegfilgrastim |
Febrile neutropenia |
|
Complete |
February 23, 2018 |
|
SE0555-000 |
Latuda |
Lurasidone |
Schizophrenia |
Do not list |
Complete |
July 3, 2012 |
January 23, 2013 |
SR0284-000 |
Latuda |
Lurasidone |
Schizophrenia |
List with criteria/condition |
Complete |
May 9, 2013 |
December 20, 2013 |
SR0331-000 |
Latuda |
lurasidone |
|
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer |
NotFiled |
|
|
|
Ledaga |
chlormethine hydrochloride |
T-cell lymphoma |
|
Active |
December 21, 2020 |
|
PC0242-000 |
Lemtrada |
Alemtuzumab |
Multiple sclerosis, relapsing-remitting |
List with criteria/condition |
Complete |
November 27, 2014 |
June 18, 2015 |
SR0405-000 |
Lemtrada |
Alemtuzumab |
Multiple sclerosis, relapsing-remitting |
|
Withdrawn |
October 1, 2013 |
|
SR0355-000 |
Levemir |
Insulin detemir |
Diabetes mellitus |
Do not list |
Complete |
December 19, 2005 |
August 2, 2006 |
SR0049-000 |
Levemir |
Insulin detemir |
Diabetes mellitus |
Do not list |
Complete |
March 10, 2009 |
August 20, 2009 |
SR0160-000 |
Levemir |
Insulin detemir |
Diabetes mellitus |
|
Withdrawn |
February 2, 2009 |
|
SR0158-000 |
Levemir |
Insulin detemir |
Diabetes mellitus Type1, Pediatrics |
Do not list |
Complete |
March 10, 2009 |
August 20, 2009 |
SR0172-000 |
pdp-levETIRAcetam |
Levetiracetam |
Epilepsy |
Reimburse with clinical criteria and/or conditions |
Active |
July 17, 2020 |
February 3, 2021 |
SR0653-000 |
Lixiana VTE |
Edoxaban |
Venous thromboembolism, treatment and recurrence prevention. |
Reimburse with clinical criteria and/or conditions |
Complete |
September 9, 2016 |
May 25, 2017 |
SR0499-000 |
Lixiana NVAF |
Edoxaban |
Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism. |
Reimburse with clinical criteria and/or conditions |
Complete |
September 9, 2016 |
March 21, 2017 |
SR0500-000 |
Lodalis |
Colesevelam hydrochloride |
Hypercholesterolemia |
Do not list at the submitted price |
Complete |
April 27, 2012 |
December 19, 2012 |
SR0274-000 |
Lokelma |
sodium zirconium cyclosilicate |
Hyperkalemia, adults |
Do not reimburse |
Complete |
May 17, 2019 |
March 25, 2020 |
SR0612-000 |
Lotemax |
Loteprednol etabonate |
Post-operative inflammation following cataract surgery |
Do not list |
Complete |
December 2, 2009 |
May 19, 2010 |
SR0186-000 |
Lucentis |
Ranibizumab injection |
Macular edema, secondary to retinal vein occlusion |
List with clinical criteria and/or conditions |
Complete |
April 25, 2012 |
October 18, 2012 |
SR0276-000 |
Lucentis |
Ranibizumab |
Macular degeneration, age-related |
List with clinical criteria and/or conditions |
Complete |
July 12, 2007 |
March 27, 2008 |
SR0098-000 |
Lucentis |
Ranibizumab |
Myopic choroidal neovascularisation |
List with criteria/condition |
Complete |
February 28, 2014 |
February 19, 2015 |
SR0373-000 |
Lucentis |
Ranibizumab |
Macular edema, diabetic |
List with clinical criteria and/or conditions |
Complete |
September 14, 2011 |
March 19, 2012 |
SR0253-000 |
Luxturna |
voretigene neparvovec |
Vision loss, inherited retinal dystrophy |
Reimburse with clinical criteria and/or conditions |
Complete |
April 23, 2020 |
November 12, 2020 |
SG0643-000 |
Lyrica |
Pregabalin |
diabetic peripheral neuropathy |
Do not list |
Complete |
March 20, 2009 |
September 23, 2009 |
SR0162-000 |
Lyrica |
Pregabalin |
Pain, Neuropathic |
Do not list |
Complete |
June 27, 2005 |
January 25, 2006 |
SR0036-000 |
Pantoloc M |
Pantoprazole magnesium |
Gastric acid secretion, reduction of |
List in a similar manner to other drugs in class |
Complete |
March 17, 2006 |
July 20, 2006 |
SR0054-000 |
Macugen |
Pegaptanib sodium |
Macular degeneration, age-related |
Do not list |
Complete |
October 20, 2005 |
May 25, 2006 |
SR0044-000 |
Mavenclad |
cladribine |
Multiple Sclerosis, relapsing-remitting |
Reimburse with clinical criteria and/or conditions |
Complete |
December 1, 2017 |
October 24, 2018 |
SR0546-000 |
Maviret |
glecaprevir pibrentasvir |
Hepatitis C, chronic |
Reimburse with clinical criteria and/or conditions |
Complete |
June 9, 2017 |
January 23, 2018 |
SR0523-000 |
Mayzent |
siponimod |
Secondary progressive multiple sclerosis |
Reimburse with clinical criteria and/or conditions |
Complete |
September 26, 2019 |
July 21, 2020 |
SR0631-000 |
MDK-Nitisinone |
nitisinone |
Hereditary tyrosinemia type 1 |
Reimburse with clinical criteria and/or conditions |
Complete |
September 29, 2017 |
April 25, 2018 |
SR0538-000 |
Mictoryl |
Propiverine hydrochloride |
Overactive bladder (OAB) |
Reimburse with clinical criteria and/or conditions |
Complete |
October 14, 2016 |
April 19, 2017 |
SR0504-000 |
Mifegymiso |
Mifepristone and misoprostol |
Medical termination of pregnancy (gestational age up to 49 days) |
|
Withdrawn |
February 12, 2016 |
|
SR0473 -000 |
Mifegymiso |
Mifepristone and misoprostol |
Medical termination of pregnancy (gestational age up to 49 days) |
Reimburse |
Complete |
October 7, 2016 |
April 18, 2017 |
SR0502-000 |
Monoferric |
Iron (III) Isomaltoside 1000 |
iron deficiency anemia |
Reimburse with clinical criteria and/or conditions |
Complete |
June 26, 2019 |
March 25, 2020 |
SR0622-000 |
Monoprost |
latanoprost |
glaucoma and ocular hypertension |
Reimburse with clinical criteria and/or conditions |
Complete |
October 25, 2017 |
April 24, 2018 |
SR0541-000 |
Movapo |
apomorphine hydrochloride |
Parkinson's disease |
Reimburse with clinical criteria and/or conditions |
Complete |
July 6, 2017 |
January 23, 2018 |
SR0527-000 |
Mozobil |
Plerixafor |
Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma |
Do not list |
Complete |
January 24, 2012 |
September 26, 2012 |
SR0265-000 |
Multaq |
Dronedarone hydrochloride |
Atrial fibrillation |
Do not list |
Complete |
September 18, 2009 |
May 27, 2010 |
SR0177-000 |
Myfortic |
Mycophenolate sodium |
Organ rejection in allogeneic renal transplants, Prophylaxis |
List in a similar manner to other drugs in class |
Complete |
March 3, 2005 |
July 8, 2005 |
SR0034-000 |
Myozyme |
Alglucosidase |
Pompe's disease |
List with clinical criteria and/or conditions |
Complete |
October 10, 2006 |
June 14, 2007 |
SR0080-000 |
Myrbetriq |
Mirabegron |
Overactive bladder |
List with criteria/condition |
Complete |
November 27, 2013 |
November 12, 2014 |
SR0363-000 |
Myrbetriq |
Mirabegron |
Overactive bladder |
|
Withdrawn |
March 8, 2013 |
|
SR0319-000 |
Naglazyme |
Galsulfase (Drug Plan Submission) |
Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) |
List with clinical criteria and/or conditions |
Complete |
August 20, 2015 |
February 19, 2016 |
SR0434-000 |
Nesina |
Alogliptin |
Diabetes mellitus, type 2 |
Do not list |
Complete |
January 30, 2014 |
January 15, 2015 |
SR0368-000 |
Neulasta |
Pegfilgrastim |
Neutropenia |
List with clinical criteria and/or conditions |
Complete |
March 29, 2004 |
October 27, 2004 |
SR0009-000 |
Neupro |
Rotigotine |
Parkinson's disease |
Do not list |
Complete |
July 31, 2013 |
May 28, 2014 |
SR0344-000 |
Neupro |
Rotigotine |
Parkinson’s disease |
List with clinical criteria and/or conditions |
Complete |
May 21, 2015 |
November 19, 2015 |
SR0432-000 |
Nexavar |
Sorafenib tablets |
Cancer, Renal cell carcinoma |
Do not list |
Complete |
July 31, 2006 |
February 28, 2007 |
SR0071-000 |
Nexplanon |
etonogestrel |
Prevention of pregnancy |
Reimburse with clinical criteria and/or conditions |
Complete |
June 3, 2020 |
October 20, 2020 |
SR0648-000 |
Nitisinone |
nitisinone |
Hereditary tyrosinemia type 1 |
Reimburse with clinical criteria and/or conditions |
Complete |
January 25, 2018 |
August 23, 2018 |
SR0554-000 |
Norprolac |
Quinagolide hydrochloride |
Hyperprolactinemia |
List with clinical criteria and/or conditions |
Complete |
November 23, 2005 |
May 17, 2006 |
SR0046-000 |
Norprolac |
Quinagolide hydrochloride |
Hyperprolactinemia |
Do not list |
Complete |
December 16, 2004 |
September 28, 2005 |
SR0026-000 |
Nplate |
Romiplostim |
Chronic immune (idiopathic) thrombocytopenic purpura (ITP) |
Do not list |
Complete |
September 29, 2009 |
May 27, 2010 |
SR0179-000 |
Nucala |
mepolizumab |
Asthma, severe eosinophilic |
Reimburse with clinical criteria and/or conditions |
Complete |
October 24, 2018 |
March 27, 2019 |
SF0593-000 |
Nucala |
Mepolizumab |
Asthma, severe eosinophilic |
Reimburse with clinical criteria and/or conditions |
Complete |
December 18, 2015 |
June 16, 2016 |
SR0461-000 |
Nucynta |
tapentadol hydrochloride |
pain, severe |
Do not reimburse |
Complete |
April 17, 2018 |
October 23, 2018 |
SR0563-000 |
NuvaRing |
Etonogestrel/ethinyl estradiol |
Contraceptive, ring |
List with clinical criteria and/or conditions |
Complete |
May 5, 2006 |
November 29, 2006 |
SR0062-000 |
Ocaliva |
Obeticholic Acid |
Primary Biliary Cholangitis |
Reimburse with clinical criteria and/or conditions |
Complete |
December 22, 2016 |
July 25, 2017 |
SR0509-000 |
Ocrevus |
ocrelizumab |
multiple sclerosis, relapsing |
Reimburse with clinical criteria and/or conditions |
Complete |
May 16, 2017 |
November 21, 2017 |
SR0519-000 |
Ocrevus |
ocrelizumab |
Primary progressive multiple sclerosis |
Reimburse with clinical criteria and/or conditions |
Complete |
October 26, 2017 |
April 26, 2018 |
SR0542-000 |
Odefsey |
emtricitabine/rilpivirine/ tenofovir alafenamide |
HIV-1 infection |
Reimburse with clinical criteria and/or conditions |
Complete |
November 24, 2016 |
May 25, 2017 |
SR0507-000 |
Ofev |
nintedanib |
chronic fibrosing interstitial lung diseases |
Reimburse with clinical criteria and/or conditions |
Active |
July 24, 2020 |
February 24, 2021 |
SR0654-000 |
Ofev |
Nintedanib |
Idiopathic pulmonary fibrosis |
List with clinical criteria and/or conditions |
Complete |
April 23, 2015 |
October 15, 2015 |
SR0426-000 |
Olmetec |
Olmesartan medoxomil |
Hypertension |
List in a similar manner to other drugs in class |
Complete |
November 28, 2008 |
May 27, 2009 |
SR0150-000 |
Olmetec Plus |
Olmesartan medoxomil + hydrochlorothiazide |
Hypertension |
List in a similar manner to other drugs in class |
Complete |
November 28, 2008 |
May 27, 2009 |
SR0151-000 |
Olumiant |
baricitinib |
Arthritis, Rheumatoid |
Reimburse with clinical criteria and/or conditions |
Complete |
December 20, 2018 |
August 2, 2019 |
SR0597-000 |
Omnaris |
Ciclesonide nasal spray |
Allergic Rhinitis (seasonal and perennial) |
Do not list |
Complete |
May 7, 2008 |
November 12, 2008 |
SR0137-000 |
Omnitrope |
Somatropin (rDNA origin) |
Growth hormone deficiency in children and adults |
|
Complete |
June 12, 2009 |
|
SR0167-000 |
Onbrez |
Indacaterol |
Chronic obstructive pulmonary disease |
List in a similar manner |
Complete |
February 29, 2012 |
August 16, 2012 |
SR0273-000 |
Onglyza |
Saxagliptin |
Diabetes mellitus, type 2 |
List with criteria/condition |
Complete |
May 9, 2013 |
November 15, 2013 |
SR0329-000 |
Onglyza |
Saxagliptin |
Diabetes mellitus (Type 2) |
Do not list |
Complete |
November 9, 2009 |
June 17, 2010 |
SR0185-000 |
Onglyza |
Saxagliptin |
Diabetes mellitus, type 2 |
|
Withdrawn |
May 28, 2012 |
|
SR0280-000 |
Onpattro |
patisiran |
Polyneuropathy in hereditary transthyretin-mediated amyloidosis |
Reimburse with clinical criteria and/or conditions |
Complete |
January 25, 2019 |
July 25, 2019 |
SR0598-000 |
Onsolis |
Fentanyl Citrate |
Pain, breakthrough cancer pain |
|
Withdrawn |
May 10, 2011 |
|
SR0229-000 |
Onsolis |
Fentanyl Citrate |
Pain, breakthrough cancer pain |
Do not list |
Complete |
August 22, 2011 |
February 15, 2012 |
SR0248-000 |
Onstryv |
safinamide |
Parkinson's disease |
Do not reimburse |
Complete |
May 29, 2019 |
March 25, 2020 |
SR0617-000 |
Onureg |
azacitidine |
Acute myeloid leukemia |
|
Pending |
|
|
PC0245-000 |
Opdivo-Yervoy |
nivolumab-ipilimumab |
Malignant Pleural Mesothelioma (MPM) |
|
Active |
October 29, 2020 |
|
PC0229-000 |
Opsumit |
Macitentan |
Pulmonary arterial hypertension |
List with clinical criteria and/or conditions |
Complete |
December 18, 2015 |
January 28, 2015 |
SR0364-000 |
Oralair |
Grass Pollen Allergen Extract |
Allergic rhinitis |
List with criteria/condition |
Complete |
September 21, 2012 |
March 20, 2013 |
SR0290-000 |
Orencia |
Abatacept |
Arthritis, Rheumatoid |
List with clinical criteria and/or conditions |
Complete |
October 26, 2006 |
June 27, 2007 |
SR0084-000 |
Orencia |
Abatacept |
Arthritis, rheumatoid |
List with clinical criteria and/or conditions |
Complete |
November 29, 2012 |
July 18, 2013 |
SR0299-000 |
Orencia |
Abatacept |
Arthritis, Rheumatoid |
List in a similar manner |
Complete |
December 2, 2009 |
June 17, 2010 |
SR0187-000 |
Orencia |
Abatacept |
Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid |
List with clinical criteria and/or conditions |
Complete |
August 29, 2008 |
April 22, 2009 |
SR0145-000 |
Orfadin |
nitisinone |
Hereditary tyrosinemia type 1 |
Reimburse with clinical criteria and/or conditions |
Complete |
August 29, 2017 |
February 21, 2018 |
SR0531-000 |
Orilissa |
elagolix |
|
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer |
NotFiled |
|
|
|
Orkambi |
lumacaftor/ivacaftor |
Cystic Fibrosis, F508del CFTR mutation |
Do not reimburse |
Complete |
January 28, 2016 |
October 26, 2016 |
SR0471-000 |
Orkambi |
lumacaftor/ivacaftor |
Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older |
Do not reimburse |
Complete |
February 22, 2018 |
September 26, 2018 |
SR0559-000 |
Otezla |
Apremilast |
Plaque psoriasis |
Do not list |
Complete |
October 8, 2014 |
July 22, 2015 |
SR0400-000 |
Otezla |
Apremilast |
Psoriasis, moderate to severe plaque |
Reimburse with clinical criteria and/or conditions |
Complete |
March 3, 2016 |
October 26, 2016 |
SR0478-000 |
Otezla |
Apremilast |
Arthritis, psoriatic |
List with criteria/condition |
Complete |
June 8, 2015 |
December 17, 2015 |
SR0437-000 |
Ozanex |
ozenoxacin |
Impetigo |
Do not reimburse |
Complete |
January 25, 2018 |
October 24, 2018 |
SR0553-000 |
Ozempic |
semaglutide |
Diabetes mellitus, type 2 |
Reimburse with clinical criteria and/or conditions |
Complete |
November 23, 2018 |
May 15, 2019 |
SR0594-000 |
Ozurdex |
dexamethasone |
Diabetic macular edema |
Do not reimburse |
Complete |
September 26, 2017 |
October 24, 2018 |
SR0535-000 |
Ozurdex |
Dexamethasone intravitreal implant |
Macular edema, central retinal vein occlusion |
Do not list |
Complete |
September 1, 2011 |
April 25, 2012 |
SR0247-000 |
Pegasys RBV |
Peginterferon alfa-2a and Ribavirin |
Hepatitis C, chronic |
List in a similar manner to other drugs in class |
Complete |
May 14, 2004 |
October 14, 2004 |
SR0013-000 |
Perseris |
risperidone |
Schizophrenia, adults |
|
Active |
January 29, 2021 |
|
SR0671-000 |
Pheburane |
Sodium phenylbutyrate |
Urea cycle disorders |
List |
Complete |
October 20, 2015 |
April 15, 2016 |
SR0452-000 |
Picato |
Ingenol mebutate |
Actinic keratosis |
Do not list |
Complete |
May 9, 2013 |
January 22, 2014 |
SR0330-000 |
Picato |
Ingenol mebutate |
Actinic keratosis |
|
Complete |
May 26, 2014 |
|
SF0382-000 |
Pifeltro |
doravirine |
HIV-1 infection |
Reimburse with clinical criteria and/or conditions |
Complete |
November 16, 2018 |
May 14, 2019 |
SR0582-000 |
Plegridy |
Peginterferon beta-1a |
Multiple sclerosis, relapsing-remitting |
List with criteria/condition |
Complete |
June 26, 2015 |
December 17, 2015 |
SR0440-000 |
Teveten Plus |
Eprosartan mesylate/ hydrochlorothiazide |
Hypertension, Essential |
List in a similar manner to other drugs in class |
Complete |
July 8, 2004 |
December 15, 2004 |
SR0016-000 |
Pradaxa |
Dabigatran etexilate |
Atrial fibrillation prevention of stroke and systemic embolism |
List with clinical criteria and/or conditions |
Complete |
March 18, 2013 |
July 18, 2013 |
SF0320-000 |
Pradaxa |
Dabigatran etexilate |
Atrial fibrillation prevention of stroke and systemic embolism |
List with clinical criteria and/or conditions |
Complete |
October 28, 2010 |
June 22, 2011 |
SR0214-000 |
Pradaxa |
Dabigatran etexilate |
Thromboembolism (venous), prevention |
Do not list |
Complete |
July 8, 2008 |
January 28, 2009 |
SR0140-000 |
Pradaxa |
Dabigatran etexilate |
Atrial fibrillation prevention of stroke and systemic embolism |
|
Cancelled |
May 31, 2010 |
|
SR0202-000 |
Praluent |
Alirocumab |
Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia |
Reimburse with clinical criteria and/or conditions |
Complete |
January 12, 2016 |
July 20, 2016 |
SR0469-000 |
Praxbind |
Idarucizumab (Drug Plan Submission) |
Reversal of dabigatran anticoagulant effects |
|
Withdrawn |
May 30, 2016 |
|
SR0492-000 |
Prevymis |
letermovir |
Cytomegalovirus infection, prophylaxis |
Reimburse with clinical criteria and/or conditions |
Complete |
December 7, 2017 |
June 20, 2018 |
SR0545-000 |
Prexige |
Lumiracoxib |
Osteoarthritis (Knee) |
Do not list |
Complete |
December 15, 2006 |
July 25, 2007 |
SR0090-000 |
Prezcobix |
Darunavir/cobicistat |
HIV Infection |
List with criteria/condition |
Complete |
May 22, 2014 |
March 18, 2015 |
SR0381-000 |
Prezista |
Darunavir |
HIV infection |
List with clinical criteria and/or conditions |
Complete |
August 29, 2006 |
February 14, 2007 |
SR0072-000 |
Prezista |
Darunavir |
HIV (treatment naive) |
List with clinical criteria and/or conditions |
Complete |
March 27, 2009 |
October 14, 2009 |
SR0163-000 |
Prezista |
Darunavir |
HIV infection (Pediatric) |
List with clinical criteria and/or conditions |
Complete |
December 22, 2009 |
June 17, 2010 |
SR0194-000 |
Pristiq |
Desvenlafaxine succinate |
Depressive, Major Disorder (MDD) |
Do not list |
Complete |
March 5, 2009 |
September 23, 2009 |
SR0159-000 |
Probuphine |
buprenorphine hydrochloride |
Opioid drug dependence, treatment |
Reimburse with clinical criteria and/or conditions |
Complete |
December 21, 2017 |
August 22, 2018 |
SR0550-000 |
Procysbi |
cysteamine bitartrate |
Nephropathic cystinosis |
Reimburse with clinical criteria and/or conditions |
Complete |
August 8, 2017 |
January 24, 2018 |
SR0526-000 |
Prolia |
Denosumab |
Osteoporosis, postmenopausal women |
List with clinical criteria and/or conditions |
Complete |
August 26, 2010 |
March 30, 2011 |
SR0208-000 |
Prolia |
Denosumab |
Osteoporosis |
Reimburse with clinical criteria and/or conditions |
Complete |
October 26, 2015 |
May 20, 2016 |
SF0453-000 |
Prolia |
Denosumab (Drug Plan Submission) |
Osteoporosis, men |
List with clinical criteria and/or conditions |
Complete |
March 10, 2015 |
September 21, 2015 |
SR0414-000 |
Quinsair |
Levofloxacin |
Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections |
Reimburse with clinical criteria and/or conditions |
Complete |
May 31, 2016 |
November 21, 2016 |
SR0493-000 |
Radicava |
edaravone |
amyotrophic lateral sclerosis |
Reimburse with clinical criteria and/or conditions |
Complete |
July 5, 2018 |
March 27, 2019 |
SR0573-000 |
Ralivia |
Tramadol hydrochloride |
Pain |
Do not list |
Complete |
October 29, 2007 |
June 25, 2008 |
SR0110-000 |
RAPAFLO |
Silodosin |
Benign prostatic hyperplasia |
Do not list |
Complete |
October 25, 2011 |
April 19, 2012 |
SR0261-000 |
Raptiva |
Efalizumab |
Psoriasis, moderate to severe chronic plaque |
List with clinical criteria and/or conditions |
Complete |
October 25, 2005 |
August 24, 2006 |
SR0043-000 |
Raptiva |
Efalizumab |
Psoriasis, moderate to severe chronic plaque |
|
Complete |
June 19, 2007 |
|
SF0102-000 |
Rasilez |
Aliskiren |
Hypertension |
Do not list |
Complete |
November 30, 2007 |
June 25, 2008 |
SR0118-000 |
Ravicti |
glycerol phenylbutyrate |
Urea cycle disorders |
Reimburse with clinical criteria and/or conditions |
Complete |
August 30, 2016 |
March 21, 2017 |
SR0497-000 |
Rebif |
Interferon beta-1a |
Clinically isolated syndrome |
Do not list |
Complete |
March 8, 2013 |
August 15, 2013 |
SR0298-000 |
Reblozyl |
luspatercept |
Myelodysplastic syndromes-associated anemia |
|
Received |
January 28, 2021 |
|
SR0670-000 |
Reblozyl |
luspatercept |
beta-thalassemia associated anemia |
|
Active |
November 26, 2020 |
|
SR0669-000 |
Relistor |
Methylnaltrexone bromide |
Constipation, Opioid-induced |
Do not list |
Complete |
May 7, 2008 |
January 28, 2009 |
SR0135-000 |
Relpax |
Eletriptan hydrobromide |
Migraine |
Do not list |
Complete |
September 21, 2004 |
March 23, 2005 |
SR0021-000 |
Remicade |
Infliximab |
Ulcerative Colitis |
Do not list |
Complete |
September 29, 2008 |
April 22, 2009 |
SR0146-000 |
Remodulin |
Treprostinil sodium |
Pulmonary arterial hypertension (NYHA Class III and IV patients) |
List with clinical criteria and/or conditions |
Complete |
February 24, 2006 |
July 20, 2006 |
SR0052-000 |
Remodulin |
Treprostinil sodium |
Pulmonary arterial hypertension (NYHA Class III and IV patients) |
Do not list |
Complete |
July 14, 2004 |
November 17, 2004 |
SR0011-000 |
Remsima |
Infliximab |
Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis |
|
Withdrawn |
May 30, 2014 |
|
SE0383-000 |
Remsima |
infliximab |
Rheumatoid arthritis |
|
Active |
September 24, 2020 |
|
SR0659-000 |
Renflexis |
infliximab |
rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis |
Reimburse with clinical criteria and/or conditions |
Complete |
September 5, 2017 |
February 20, 2018 |
SE0532-000 |
Repatha |
Evolocumab |
Primary hyperlipidemia; mixed dyslipidemia |
List with clinical criteria and/or conditions |
Complete |
June 30, 2015 |
February 19, 2016 |
SR0441-000 |
Repatha |
Evolocumab |
Primary hyperlipidemia and mixed dyslipidemia |
Reimburse with clinical criteria and/or conditions |
Complete |
February 17, 2017 |
November 22, 2017 |
SR0515-000 |
Replagal |
Agalsidase alfa |
Fabry Disease |
Do not list |
Complete |
February 19, 2004 |
November 24, 2004 |
SR0006-000 |
Resotran |
Prucalopride |
Constipation, chronic |
Do not list |
Complete |
January 30, 2012 |
July 19, 2012 |
SR0266-000 |
Spiriva Respimat |
Tiotropium bromide |
Chronic obstructive pulmonary disease |
List with clinical criteria and/or conditions |
Complete |
December 23, 2014 |
July 16, 2015 |
SR0412-000 |
Revatio |
Sildenafil citrate |
Pulmonary arterial hypertension (WHO class II and III) |
List in a similar manner |
Complete |
September 20, 2006 |
February 14, 2007 |
SR0076-000 |
Revestive |
teduglutide |
Short Bowel Syndrome (SBS), pediatrics |
Reimburse with clinical criteria and/or conditions |
Complete |
May 29, 2019 |
November 19, 2019 |
SR0606-000 |
Revestive |
Teduglutide |
Short bowel syndrome |
Reimburse with clinical criteria and/or conditions |
Complete |
November 26, 2015 |
July 27, 2016 |
SR0459-000 |
Revolade |
Eltrombopag olamine |
Chronic immune thrombocytopenic purpura |
Do not list |
Complete |
April 26, 2011 |
October 24, 2011 |
SR0230-000 |
Revolade |
eltrombopag |
|
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer |
NotFiled |
|
|
|
Revolade |
Eltrombopag |
Thrombocytopenia associated with chronic hepatitis c infection |
List with criteria/condition |
Complete |
March 31, 2014 |
March 18, 2015 |
SR0377-000 |
Rexulti |
Brexpiprazole |
schizophrenia |
Reimburse with clinical criteria and/or conditions |
Complete |
February 3, 2017 |
November 22, 2017 |
SR0514-000 |
Reyataz |
Atazanavir |
HIV infection |
List in a similar manner to other drugs in class |
Complete |
December 16, 2003 |
May 27, 2004 |
SR0002-000 |
Rinvoq |
upadacitinib |
Arthritis, Rheumatoid |
Reimburse with clinical criteria and/or conditions |
Complete |
July 4, 2019 |
February 4, 2020 |
SR0614-000 |
Rinvoq |
upadacitinib |
Psoriatic Arthritis, Adults. |
|
Active |
January 4, 2021 |
|
SR0658-000 |
Rituxan |
Rituximab |
Arthritis, Rheumatoid |
List with clinical criteria and/or conditions |
Complete |
June 26, 2006 |
February 14, 2007 |
SR0068-000 |
Rituxan |
Rituximab |
Granulomatosis with polyangiitis and microscopic polyangiitis |
List with clinical criteria and/or conditions |
Complete |
February 24, 2012 |
August 16, 2012 |
SR0270-000 |
Rosiver |
Ivermectin |
Rosacea |
List with criteria/condition |
Complete |
April 30, 2015 |
November 19, 2015 |
SR0429-000 |
Ruzurgi |
amifampridine |
Lambert-Eaton myasthenic syndrome |
|
Active |
October 5, 2020 |
|
SR0660-000 |
Rybelsus |
semaglutide |
diabetes mellitus, type 2 |
|
Active |
November 26, 2020 |
|
SR0637-000 |
Samsca |
Tolvaptan |
Hyponatremia, non-hypovolemic |
Do not list |
Complete |
July 3, 2012 |
February 13, 2013 |
SR0283-000 |
Saphris |
Asenapine |
Schizophrenia |
Do not list |
Complete |
December 12, 2011 |
June 14, 2012 |
SR0262-000 |
Saphris |
Asenapine |
Bipolar I disorder |
List with clinical criteria and/or conditions |
Complete |
December 12, 2011 |
June 14, 2012 |
SR0262-001 |
Sativex |
Delta-9-tetrahydrocannabinol/cannabidiol |
Pain, Neuropathic (adjunctive) in MS. |
Do not list |
Complete |
February 27, 2007 |
September 26, 2007 |
SR0092-000 |
Sativex |
Delta-9-tetrahydrocannabinol/cannabidiol |
Pain, cancer (adjunctive analgesia to maximum tolerated strong opioids) |
Do not list |
Complete |
August 7, 2007 |
February 20, 2008 |
SR0106-000 |
Saxenda |
liraglutide |
Chronic weight management in adults |
|
Active |
December 23, 2020 |
|
SR0668-000 |
Sebivo |
Telbivudine |
Hepatitis B (chronic) |
Do not list |
Complete |
December 4, 2006 |
September 26, 2007 |
SR0088-000 |
Seebri |
Glycopyrronium bromide |
Chronic obstructive pulmonary disease |
List with criteria/condition |
Complete |
November 30, 2012 |
May 15, 2013 |
SR0300-000 |
Segluromet |
ertugliflozin and metformin hydrochloride |
Diabetes mellitus, Type 2 |
Do not reimburse |
Complete |
April 30, 2018 |
January 23, 2019 |
SR0566-000 |
Semglee |
insulin glargine |
Diabetes mellitus, Type 1 & 2 |
|
Withdrawn |
November 14, 2018 |
|
SE0589-000 |
Sensipar |
Cinacalcet hydrochloride |
Secondary hyper-parathyroidism in chronic kidney disease |
Do not list |
Complete |
August 20, 2004 |
March 23, 2005 |
SR0018-000 |
Signifor |
Pasireotide diaspartate |
Cushing’s disease |
Do not list |
Complete |
February 27, 2014 |
February 24, 2015 |
SR0372-000 |
Siliq |
brodalumab |
Psoriasis, moderate to severe plaque |
Reimburse with clinical criteria and/or conditions |
Complete |
December 14, 2017 |
June 20, 2018 |
SR0547-000 |
Silkis |
Calcitriol |
Psoriasis, mild to moderate plaque |
Do not list |
Complete |
March 15, 2010 |
September 22, 2010 |
SR0199-000 |
Simbrinza |
Brinzolamide / brimonidine |
Glaucoma and ocular hypertension |
List |
Complete |
November 3, 2014 |
June 17, 2015 |
SR0403-000 |
Simponi |
Golimumab |
Arthritis, psoriatic |
List in a similar manner |
Complete |
September 3, 2009 |
March 17, 2010 |
SR0195-000 |
Simponi |
Golimumab |
Ankylosing spondylitis |
List in a similar manner |
Complete |
September 3, 2009 |
March 17, 2010 |
SR0196-000 |
Simponi |
Golimumab |
Ulcerative colitis |
Do not list at the submitted price |
Complete |
July 12, 2013 |
March 19, 2014 |
SR0341-000 |
Simponi |
Golimumab |
Arthritis, Rheumatoid |
List in a similar manner |
Complete |
September 3, 2009 |
March 17, 2010 |
SR0174-000 |
Sivextro |
Tedizolid phosphate |
Acute bacterial skin and skin structure infections |
|
Withdrawn |
January 16, 2015 |
|
SR0413-000 |
Skyrizi |
risankizumab |
Psoriasis, moderate to severe plaque |
Reimburse with clinical criteria and/or conditions |
Complete |
October 22, 2018 |
May 28, 2019 |
SR0583-000 |
Soliqua |
lixisenatide + insulin glargine |
Diabetes mellitus, Type 2 |
Reimburse with clinical criteria and/or conditions |
Complete |
May 18, 2018 |
December 24, 2018 |
SR0564-000 |
Soliris |
Eculizumab |
Paroxysmal nocturnal hemoglobinuria (PNH) |
Do not list |
Complete |
September 18, 2009 |
February 18, 2010 |
SR0176-000 |
Soliris |
Eculizumab |
Atypical hemolytic uremic syndrome |
|
Complete |
February 9, 2015 |
|
SF0416-000 |
Soliris |
eculizumab |
Neuromyelitis optica spectrum disorder |
Reimburse with clinical criteria and/or conditions |
Complete |
February 25, 2020 |
August 19, 2020 |
SR0640-000 |
Soliris |
eculizumab |
Myasthenia Gravis (gMG), adults |
Reimburse with clinical criteria and/or conditions |
Complete |
April 1, 2020 |
October 19, 2020 |
SR0605-000 |
Soliris |
Eculizumab |
Hemolytic Uremic Syndrome, Atypical |
Do not list |
Complete |
January 7, 2013 |
July 18, 2013 |
SR0304-000 |
Somavert |
Pegvisomant |
acromegaly |
Do not list |
Complete |
January 25, 2006 |
August 2, 2006 |
SR0050-000 |
Sovaldi |
Sofosbuvir |
Hepatitis C, chronic |
List with criteria/condition |
Complete |
October 1, 2013 |
August 18, 2014 |
SR0356-000 |
Sovaldi |
sofosbuvir |
Hepatitis C, chronic |
Reimburse with clinical criteria and/or conditions |
Complete |
January 6, 2016 |
May 18, 2016 |
SF0464-000 |
Spinraza |
nusinersen |
Spinal Muscular Atrophy |
Reimburse with clinical criteria and/or conditions |
Complete |
June 28, 2017 |
December 22, 2017 |
SR0525-000 |
Spinraza |
Nusinersen |
Spinal Muscular Atrophy |
Reimburse with clinical criteria and/or conditions |
Complete |
July 24, 2018 |
February 27, 2019 |
SR0576-000 |
Spravato |
esketamine hydrochloride |
Major depressive disorder (MDD), adults |
Do not reimburse |
Active |
June 24, 2019 |
December 16, 2020 |
SR0621-000 |
Spriafil |
Posaconazole |
Aspergillus and Candida infections |
Do not list |
Complete |
May 24, 2007 |
January 30, 2008 |
SR0097-000 |
Stalevo |
Carbidopa, levodopa and entacapone |
Parkinsons Disease |
List in a similar manner |
Complete |
April 15, 2008 |
October 16, 2008 |
SR0131-000 |
Steglatro |
ertugliflozin |
Diabetes mellitus, Type 2 |
Do not reimburse |
Complete |
April 30, 2018 |
January 23, 2019 |
SR0565-000 |
Stelara |
Ustekinumab |
Psoriasis |
List with clinical criteria and/or conditions |
Complete |
January 7, 2009 |
June 17, 2009 |
SR0156-000 |
Stelara |
Ustekinumab |
Arthritis, psoriatic |
Do not list at the submitted price |
Complete |
October 30, 2013 |
October 20, 2014 |
SR0359-000 |
Strattera |
Atomoxetine hydrochloride |
Attention deficit hyperactivity disorder |
Do not list |
Complete |
January 25, 2005 |
September 28, 2005 |
SR0031-000 |
Strattera |
Atomoxetine hydrochloride |
Attention deficit hyperactivity disorder |
|
Complete |
September 25, 2006 |
|
SF0085-000 |
Strensiq |
Asfotase alfa |
Hypophosphatasia, pediatric-onset |
List with criteria/condition |
Complete |
August 21, 2015 |
March 23, 2016 |
SR0443-000 |
Stribild |
Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Disoproxil Fumarate |
HIV infection |
List with criteria/condition |
Complete |
November 30, 2012 |
May 15, 2013 |
SR0301-000 |
Sublinox |
Zolpidem tartrate |
Insomnia |
Do not list |
Complete |
March 7, 2013 |
September 25, 2013 |
SR0314-000 |
Sublocade |
buprenorphine |
Opioid use disorder, treatment |
Reimburse with clinical criteria and/or conditions |
Complete |
December 20, 2018 |
June 19, 2019 |
SR0579-000 |
Suboxone |
Buprenorphine/naloxone |
Opioid drug dependence (Substitution treatment) |
List with clinical criteria and/or conditions |
Complete |
March 6, 2008 |
September 24, 2008 |
SR0128-000 |
Sunvepra |
Asunaprevir |
Hepatitis C, chronic |
Reimburse with clinical criteria and/or conditions |
Complete |
February 13, 2015 |
July 20, 2016 |
SR0418-000 |
Sutent |
Sunitinib |
Gastrointestinal stromal tumour (GIST) |
List with clinical criteria and/or conditions |
Complete |
July 20, 2006 |
March 28, 2007 |
SR0069-000 |
Sutent |
Sunitinib malate |
Cancer, Metastatic renal cell carcinoma |
Do not list |
Complete |
September 20, 2006 |
April 26, 2007 |
SR0077-000 |
Symdeko |
tezacaftor/ivacaftor |
|
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer |
NotFiled |
|
|
|
Symtuza |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide |
HIV-1 infection |
Reimburse with clinical criteria and/or conditions |
Complete |
December 22, 2017 |
July 25, 2018 |
SR0552-000 |
Synjardy |
Empagliflozin and metformin |
Diabetes mellitus (Type 2) |
Reimburse with clinical criteria and/or conditions |
Complete |
April 29, 2016 |
October 25, 2016 |
SR0489-000 |
Tagrisso |
osimertinib |
Non-small cell lung cancer |
|
Pending |
|
|
PC0246-000 |
Takhzyro |
lanadelumab |
Hereditary angioedema, prevention |
Reimburse with clinical criteria and/or conditions |
Complete |
May 29, 2019 |
November 19, 2019 |
SR0618-000 |
Taltz |
ixekizumab |
Ankylosing spondylitis |
Reimburse with clinical criteria and/or conditions |
Complete |
September 20, 2019 |
March 24, 2020 |
SR0630-000 |
Taltz |
ixekizumab |
Arthritis, psoriatic |
Reimburse with clinical criteria and/or conditions |
Complete |
February 20, 2018 |
August 21, 2018 |
SR0558-000 |
Taltz |
Ixekizumab |
Psoriasis, moderate to severe plaque |
Reimburse with clinical criteria and/or conditions |
Complete |
March 23, 2016 |
October 25, 2016 |
SR0481-000 |
Talzenna |
talazoparib |
Breast cancer |
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer |
NotFiled |
|
|
|
Tarceva |
Erlotinib |
Cancer, Lung , non-small cell |
List with clinical criteria and/or conditions |
Complete |
July 19, 2005 |
December 7, 2005 |
SR0037-000 |
Targin |
Oxycodone / naloxone |
Pain, Moderate to severe and relief of opioid-induced constipation |
|
Cancelled |
November 30, 2010 |
|
SR0219-000 |
Targin |
Oxycodone HCI / naloxone HCI |
Pain, moderate to severe and relief of opioid-induced constipation |
Do not list |
Complete |
July 5, 2011 |
January 25, 2012 |
SR0241-000 |
TBC |
Darunavir / cobicistat |
HIV infection |
|
Withdrawn |
April 4, 2014 |
|
SR0378-000 |
TBC |
idecabtagene vicleucel |
Multiple myeloma |
|
Active |
December 16, 2020 |
|
PG0240-000 |
TBC |
brexucabtagene autoleucel |
Mantle cell lymphoma |
|
Active |
December 18, 2020 |
|
PG0219-000 |
TBC |
triheptanoin |
Long-chain fatty acid oxidation disorders |
|
Pending |
|
|
SR0684-000 |
TBC |
risdiplam |
Spinal muscular atrophy |
|
Active |
November 19, 2020 |
|
SR0661-000 |
TBC |
budesonide/ glycopyrronium /formoterol fumarate |
chronic obstructive pulmonary disease (COPD) |
|
Active |
January 28, 2021 |
|
SR0675-000 |
TBC |
filgotinib |
Arthritis, Rheumatoid |
|
Withdrawn |
August 4, 2020 |
|
SR0656-000 |
TBC |
inclisiran |
Primary hypercholesterolemia |
|
Pending |
|
|
SR0681-000 |
TBC |
etonogestrel |
Prevention of pregnancy |
|
Withdrawn |
September 26, 2019 |
|
SR0629-000 |
TBC |
filgrastim |
Prevention or treatment of neutropenia in various indications |
|
Cancelled |
November 1, 2018 |
|
SE0585-000 |
TBC |
filgrastim |
|
|
Cancelled |
|
|
SE0596-000 |
TBC |
elexacaftor/tezacaftor/ivacaftor and ivacaftor |
Cystic fibrosis, F508del CFTR mutation |
|
Active |
January 22, 2021 |
|
SR0673-000 |
TBC |
halobetasol propionate and tazarotene |
Psoriasis, moderate to severe plaque |
|
Withdrawn |
February 4, 2019 |
|
SR0600-000 |
TBC |
ravulizumab |
Paroxysmal nocturnal hemoglobinuria. |
|
Withdrawn |
July 4, 2019 |
|
SR0623-000 |
Tecfidera |
Dimethyl fumarate |
Multiple sclerosis, relapsing-remitting |
List with criteria/condition |
Complete |
February 4, 2013 |
September 25, 2013 |
SR0309-000 |
Technivie |
Ombitasvir/ paritaprevir/ ritonavir |
Hepatitis C, chronic |
List with clinical criteria and/or conditions |
Complete |
September 4, 2015 |
March 18, 2016 |
SR0444-000 |
Tegsedi |
inotersen |
hereditary transthyretin amyloidosis |
Reimburse with clinical criteria and/or conditions |
Complete |
February 22, 2019 |
December 18, 2019 |
SR0603-000 |
Telzir |
Fosamprenavir calcium |
HIV infection |
List in a similar manner to other drugs in class |
Complete |
January 24, 2005 |
June 16, 2005 |
SR0030-000 |
Thelin |
Sitaxsentan sodium |
Pulmonary arterial hypertension (WHO class II and III) |
Do not list |
Complete |
May 5, 2008 |
January 28, 2009 |
SR0132-000 |
Thelin |
Sitaxsentan sodium |
Pulmonary arterial hypertension (WHO class II and III) |
Do not list |
Complete |
June 22, 2007 |
January 30, 2008 |
SR0099-000 |
Tivicay |
Dolutegravir |
HIV infection |
List |
Complete |
October 18, 2013 |
August 18, 2014 |
SR0357-000 |
Toctino |
Alitretinoin |
Eczema |
List with clinical criteria and/or conditions |
Complete |
May 6, 2011 |
October 24, 2011 |
SR0232-000 |
Toviaz |
Fesoterodine fumarate |
Overactive bladder |
List in a similar manner |
Complete |
April 27, 2012 |
October 18, 2012 |
SR0277-000 |
Trajenta |
Linagliptin |
Diabetes mellitus, type 2 |
List with clinical criteria and/or conditions |
Complete |
August 23, 2011 |
February 15, 2012 |
SR0244-000 |
Tramacet |
Tramadol hydrochloride /acetaminophen |
Acute pain |
Do not list |
Complete |
October 2, 2006 |
May 17, 2007 |
SR0079-000 |
Translarna |
ataluren |
|
|
Cancelled |
|
|
SR0607-000 |
Trelstar |
Triptorelin pamoate |
Cancer, prostate |
List in a similar manner to other drugs in class |
Complete |
February 27, 2006 |
July 20, 2006 |
SR0051-000 |
Tremfya |
guselkumab |
Psoriasis, moderate to severe plaque |
Reimburse with clinical criteria and/or conditions |
Complete |
August 25, 2017 |
February 21, 2018 |
SR0530-000 |
Tresiba |
insulin degludec |
Diabetes mellitus, Type 1 & 2 |
Reimburse with clinical criteria and/or conditions |
Complete |
May 31, 2017 |
November 20, 2017 |
SR0521-000 |
Tridural |
Tramadol hydrochloride |
Pain |
Do not list |
Complete |
November 29, 2007 |
April 17, 2008 |
SR0117-000 |
Trintellix |
vortioxetine hydrobromide |
Major depressive disorder (MDD), adults. |
Reimburse with clinical criteria and/or conditions |
Complete |
May 1, 2019 |
February 12, 2020 |
SR0611-000 |
Trintellix |
Vortioxetine |
Depression, major depressive disorder |
|
Withdrawn |
October 31, 2014 |
|
SR0402-000 |
Triumeq |
Dolutegravir / abacavir / lamivudine |
HIV Infection |
List with criteria/condition |
Complete |
July 31, 2014 |
April 17, 2015 |
SR0387-000 |
Trosec |
Trospium chloride |
Bladder, overactive |
List with clinical criteria and/or conditions |
Complete |
March 24, 2006 |
August 24, 2006 |
SR0055-000 |
Trulicity |
Dulaglutide |
Diabetes mellitus, Type 2 |
Reimburse with clinical criteria and/or conditions |
Complete |
December 22, 2015 |
June 16, 2016 |
SR0462-000 |
Truvada |
Emtricitabine/tenofovir disoproxil fumarate |
HIV infection |
List with clinical criteria and/or conditions |
Complete |
May 29, 2006 |
October 25, 2006 |
SR0063-000 |
Truvada |
Emtricitabine/tenofovir disoproxil fumarate |
HIV infection |
List with clinical criteria and/or conditions |
Complete |
July 7, 2008 |
December 17, 2008 |
SF0138-000 |
Truvada |
Emtricitabine/tenofovir disoproxil fumarate |
HIV-1 infection, pre-exposure prophylaxis |
Reimburse with clinical criteria and/or conditions |
Complete |
March 3, 2016 |
August 24, 2016 |
SR0479-000 |
Tukysa |
tucatinib |
Advanced or Metastatic Breast Cancer |
|
Pending |
|
|
PC0243-000 |
Twynsta |
Telmisartan/ Amlodipine |
Hypertension |
List |
Complete |
August 23, 2011 |
December 16, 2011 |
SR0245-000 |
Twynsta |
Telmisartan / Amlodipine |
Hypertension |
|
Cancelled |
July 9, 2010 |
|
SR0207-000 |
Tysabri |
Natalizumab |
Multiple Sclerosis, relapsing-remitting |
List with clinical criteria and/or conditions |
Complete |
May 6, 2008 |
February 25, 2009 |
SR0133-000 |
Tysabri |
Natalizumab |
Multiple Sclerosis, relapsing-remitting |
Do not list |
Complete |
October 26, 2006 |
April 26, 2007 |
SR0082-000 |
Uloric |
Febuxostat |
Gout |
List with clinical criteria and/or conditions |
Complete |
October 27, 2010 |
April 25, 2011 |
SR0213-000 |
Unituxin |
dinutuximab |
Neuroblastoma |
|
Active |
November 23, 2020 |
|
PC0222-000 |
Uptravi |
Selexipag |
Pulmonary arterial hypertension (WHO class II and III) |
Reimburse with clinical criteria and/or conditions |
Complete |
March 31, 2016 |
October 28, 2016 |
SR0482-000 |
Vantas |
Histrelin acetate |
Cancer, prostate |
Do not list |
Complete |
September 20, 2006 |
April 26, 2007 |
SR0078-000 |
Vascepa |
icosapent ethyl |
Ischemic events in statin-treated patients |
Reimburse with clinical criteria and/or conditions |
Complete |
June 17, 2019 |
July 16, 2020 |
SR0619-000 |
Velphoro |
sucroferric oxyhydroxide |
Hyperphosphatemia, end-stage renal disease |
Reimburse with clinical criteria and/or conditions |
Complete |
June 12, 2018 |
January 2, 2019 |
SR0571-000 |
Veltassa |
patiromer |
Hyperkalemia, adults (chronic kidney disease) |
|
Active |
October 30, 2020 |
|
SR0665-000 |
Vemlidy |
tenofovir alafenamide |
Hepatitis B, chronic |
Reimburse with clinical criteria and/or conditions |
Complete |
September 28, 2017 |
March 26, 2018 |
SR0537-000 |
Venclexta |
venetoclax |
Acute myeloid leukemia |
|
Active |
January 8, 2021 |
|
PC0238-000 |
Venclexta |
venetoclax |
Acute myeloid leukemia |
|
Active |
January 22, 2021 |
|
PC0239-000 |
Verkazia |
cyclosporine |
Severe vernal keratoconjunctivitis, pediatric (≥4 years) |
Reimburse with clinical criteria and/or conditions |
Complete |
May 22, 2019 |
November 18, 2019 |
SR0615-000 |
Vesicare |
Solifenacin succinate |
Bladder, overactive |
List with clinical criteria and/or conditions |
Complete |
January 5, 2009 |
June 17, 2009 |
SR0155-000 |
Vesicare |
Solifenacin succinate |
Bladder, overactive |
Do not list |
Complete |
July 24, 2006 |
January 24, 2007 |
SR0070-000 |
VesiFlow |
Solifenacin succinate / tamsulosin hydrochloride |
Benign prostatic hyperplasia |
|
Withdrawn |
April 6, 2015 |
|
SR0424-000 |
VFEND |
Voriconazole |
Aspergillosis, Invasive |
List with clinical criteria and/or conditions |
Complete |
October 25, 2004 |
April 14, 2005 |
SR0023-000 |
VFEND |
Voriconazole |
Candidemia |
List with clinical criteria and/or conditions |
Complete |
March 24, 2006 |
October 25, 2006 |
SR0056-000 |
VFEND |
Voriconazole |
Aspergillosis, Invasive |
|
Withdrawn |
August 24, 2004 |
|
SR0020-000 |
Viacoram |
perindopril arginine / amlodipine |
Hypertension, essential |
Reimburse with clinical criteria and/or conditions |
Complete |
May 2, 2016 |
October 26, 2016 |
SR0490-000 |
Viberzi |
eluxadoline |
Irritable bowel syndrome with diarrhea |
Do not reimburse |
Complete |
February 23, 2018 |
August 24, 2018 |
SR0560-000 |
Victoza |
Liraglutide |
Diabetes Mellitus, Type 2 |
|
Withdrawn |
October 20, 2016 |
|
SR0505-000 |
Victoza |
Liraglutide |
Diabetes mellitus, Type 2 |
Do not list |
Complete |
November 29, 2010 |
September 28, 2011 |
SR0217-000 |
Victrelis |
Boceprevir |
Hepatitis C, chronic |
List with criteria/condition |
Complete |
December 21, 2012 |
June 13, 2013 |
SF0303-000 |
Victrelis |
Boceprevir |
Hepatitis C, chronic |
List with criteria/condition |
Complete |
February 19, 2013 |
June 13, 2013 |
SF0312-000 |
Victrelis |
Boceprevir |
Hepatitis C, chronic |
List with clinical criteria and/or conditions |
Complete |
May 3, 2011 |
October 24, 2011 |
SR0231-000 |
Viibryd |
vilazodone |
|
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer |
NotFiled |
|
|
|
Vimizim |
Elosulfase alfa |
Mucopolysaccharidosis IVA (Morquio A syndrome) |
Do not list |
Complete |
August 5, 2014 |
March 25, 2015 |
SR0389-000 |
Vimizim |
Elosulfase alfa |
Mucopolysaccharidosis IVA (Morquio A syndrome) |
Reimburse with clinical criteria and/or conditions |
Complete |
November 10, 2015 |
May 20, 2016 |
SR0456-000 |
Vimpat |
Lacosamide |
Epilepsy, partial onset seizures |
List with clinical criteria and/or conditions |
Complete |
October 25, 2010 |
April 25, 2011 |
SR0212-000 |
Viread |
Tenofovir disoproxil fumarate |
HIV infection |
|
Complete |
July 7, 2008 |
|
SF0139-000 |
Viread |
Tenofovir disoproxil fumarate |
Hepatitis B (chronic) |
List with clinical criteria and/or conditions |
Complete |
October 2, 2008 |
March 18, 2009 |
SR0148-000 |
Viread |
Tenofovir disoproxil fumarate |
HIV infection |
Do not list |
Complete |
February 23, 2004 |
August 25, 2004 |
SR0008-000 |
Viread |
Tenofovir disoproxil fumarate |
HIV infection |
List with clinical criteria and/or conditions |
Complete |
August 11, 2005 |
March 15, 2006 |
SR0040-000 |
Visanne |
Dienogest |
Pain, pelvic pain associated with endometriosis |
List with clinical criteria and/or conditions |
Complete |
October 18, 2011 |
April 19, 2012 |
SR0255-000 |
Vitrakvi |
larotrectinib |
Solid tumours with NTRK gene fusion |
|
Active |
November 16, 2020 |
|
PC0221-000 |
Volibris |
Ambrisentan |
Pulmonary arterial hypertension (WHO class II and III) |
List with clinical criteria and/or conditions |
Complete |
July 9, 2008 |
December 17, 2008 |
SR0142-000 |
Vonvendi |
von Willebrand Factor [recombinant] |
von Willebrand disease, adults, treatment and perioperative management |
|
Active |
April 29, 2020 |
|
ST0639-000 |
Vosevi |
sofosbuvir velpatasvir voxilaprevir |
Hepatitis C, chronic |
Reimburse with clinical criteria and/or conditions |
Complete |
July 28, 2017 |
January 23, 2018 |
SR0529-000 |
VPRIV |
Velaglucerase alfa |
Gaucher Disease |
List with clinical criteria and/or conditions |
Complete |
October 28, 2010 |
April 25, 2011 |
SR0215-000 |
Vyndaqel |
tafamidis |
transthyretin-mediated amyloidosis |
Reimburse with clinical criteria and/or conditions |
Complete |
July 4, 2019 |
February 19, 2020 |
SR0625-000 |
Vyvanse |
Lisdexamfetamine dimesylate |
Attention deficit hyperactivity disorder |
Do not list |
Complete |
July 10, 2009 |
December 18, 2009 |
SR0171-000 |
Vyxeos |
daunorubicin and cytarabine |
Acute myeloid leukemia |
|
Active |
January 22, 2021 |
|
PC0237-000 |
Vyzulta |
latanoprostene bunod |
Open-angle glaucoma or ocular hypertension |
Reimburse with clinical criteria and/or conditions |
Complete |
November 23, 2018 |
July 24, 2019 |
SR0590-000 |
Xarelto |
Rivaroxaban |
Venous thromboembolism, prevention |
|
Complete |
June 24, 2011 |
|
SF0239-000 |
Xarelto |
Rivaroxaban |
Thromboembolism (venous), prevention |
List with clinical criteria and/or conditions |
Complete |
May 7, 2008 |
December 17, 2008 |
SR0134-000 |
Xarelto |
Rivaroxaban |
Deep-vein thrombosis without symptomatic pulmonary embolism |
|
Complete |
October 10, 2012 |
|
SF0295-000 |
Xarelto |
rivaroxaban |
Prevention of stroke and cardiovascular events in coronary and peripheral artery disease. |
Reimburse with clinical criteria and/or conditions |
Complete |
May 24, 2018 |
November 20, 2018 |
SR0569-000 |
Xarelto |
Rivaroxaban |
|
List with clinical criteria and/or conditions |
Complete |
March 18, 2013 |
July 18, 2013 |
SF0321-00 |
Xarelto |
Rivaroxaban |
Venous thromboembolic events, pulmonary embolism |
List with criteria/condition |
Complete |
May 6, 2013 |
March 26, 2014 |
SR0327-000 |
Xarelto |
Rivaroxaban |
Atrial fibrillation, stroke prevention |
List with clinical criteria and/or conditions |
Complete |
October 21, 2011 |
April 19, 2012 |
SR0257-000 |
Xarelto |
Rivaroxaban |
Deep-vein thrombosis without symptomatic pulmonary embolism |
List with clinical criteria and/or conditions |
Complete |
February 27, 2012 |
August 16, 2012 |
SR0271-000 |
Xeljanz |
Tofacitinib |
Arthritis, rheumatoid |
List with criteria/condition |
Complete |
May 5, 2014 |
April 17, 2015 |
SR0380-000 |
Xeljanz |
tofacitinib |
Ulcerative colitis |
Reimburse with clinical criteria and/or conditions |
Complete |
June 27, 2018 |
February 27, 2019 |
SR0572-000 |
Xeljanz |
tofacitinib |
|
|
Cancelled |
|
|
SR0575-000 |
Xeomin |
Clostridium botulinum neurotoxin type A, free from complexing proteins |
Blepharospasm |
List in a similar manner |
Complete |
June 12, 2009 |
December 16, 2009 |
SR0168-000 |
Xeomin |
Clostridium botulinum neurotoxin type A, free from complexing proteins |
Cervical Dystonia |
List in a similar manner |
Complete |
June 12, 2009 |
December 16, 2009 |
SR0192-000 |
Xeomin |
Clostridium botulinum neurotoxin type A, free from complexing proteins |
Spasticity, Post-stroke |
Do not list |
Complete |
June 12, 2009 |
December 16, 2009 |
SR0193-000 |
Xeomin |
incobotulinumtoxin A |
Chronic sialorrhea associated with neurological disorders |
|
Pending |
|
|
SR0678-000 |
Xermelo |
telotristat |
carcinoid syndrome |
Do not reimburse |
Complete |
September 27, 2018 |
June 26, 2019 |
SR0580-000 |
Xgeva |
Denosumab (Drug Plan Submission) |
Prevention of skeletal-related events due to bone metastases from breast cancer |
List with clinical criteria and/or conditions |
Complete |
July 31, 2015 |
February 25, 2016 |
SR0433-000 |
Xgeva |
Denosumab (Drug Plan Submission) |
Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer |
List with clinical criteria and/or conditions |
Complete |
July 31, 2015 |
March 23, 2016 |
SR0433-001 |
XGEVA |
Denosumab |
Prevention of skeletal-related events due to bone metastases from solid tumours |
List with clinical criteria and/or conditions |
Complete |
June 6, 2011 |
November 16, 2011 |
SR0235-000 |
Xiaflex |
Collagenase clostridium histolyticum |
Dupuytren’s contracture |
List with criteria/condition |
Complete |
August 30, 2012 |
March 27, 2013 |
SR0287-000 |
XigDuo |
dapagliflozin/metformin hydrochloride |
Diabetes Mellitus, Type 2 |
Reimburse with clinical criteria and/or conditions |
Complete |
January 7, 2016 |
July 20, 2016 |
SR0468-000 |
Zytram XL |
Tramadol hydrochloride |
Pain, acute |
|
Withdrawn |
November 3, 2006 |
|
SR0086-000 |
Zytram XL |
Tramadol hydrochloride |
Pain, acute |
Do not list |
Complete |
March 15, 2007 |
September 26, 2007 |
SR0093-000 |
Xofluza |
baloxavir marboxil |
Influenza |
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer |
NotFiled |
|
|
|
Xolair |
Omalizumab |
Chronic idiopathic urticaria |
List with clinical criteria and/or conditions |
Complete |
September 22, 2014 |
May 7, 2015 |
SR0398-000 |
Xolair |
Omalizumab |
Asthma, severe persistent |
|
Cancelled |
April 18, 2005 |
|
SR0035-000 |
Xolair |
Omalizumab (Drug Plan Submission) |
Asthma, severe persistent |
Reimburse with clinical criteria and/or conditions |
Complete |
November 18, 2015 |
May 18, 2016 |
SR0457-000 |
Xolair |
Omalizumab |
Asthma, severe persistent |
Do not list |
Complete |
October 13, 2005 |
March 7, 2006 |
SR0045-000 |
Xultophy |
insulin degludec + liraglutide |
Diabetes mellitus, Type 2 |
Reimburse with clinical criteria and/or conditions |
Complete |
January 30, 2019 |
October 24, 2019 |
SR0599-000 |
Xyrem |
Sodium oxybate |
Narcolepsy |
Do not list |
Complete |
July 9, 2008 |
January 28, 2009 |
SR0141-000 |
Xyrem |
Sodium oxybate |
Narcolepsy |
|
Withdrawn |
August 29, 2007 |
|
SR0107-000 |
Yasmin |
Drospirenone /ethinyl estradiol |
Contraceptive, oral |
List |
Complete |
January 20, 2005 |
June 16, 2005 |
SR0029-000 |
Zavesca |
Miglustat |
Gaucher disease |
Do not list |
Complete |
May 13, 2004 |
November 24, 2004 |
SR0012-000 |
Zaxine |
Rifaximin |
Hepatic encephalopathy |
List with criteria/condition |
Complete |
August 5, 2014 |
April 16, 2015 |
SR0388-000 |
Zeldox |
Ziprasidone hydrochloride |
Schizophrenia and related psychotic disorders |
List with clinical criteria and/or conditions |
Complete |
January 10, 2008 |
August 14, 2008 |
SR0124-000 |
Zenhale |
Mometasone/formoterol |
Asthma |
List with clinical criteria and/or conditions |
Complete |
June 6, 2012 |
December 19, 2012 |
SF0281-000 |
Zepatier |
Elbasvir/grazoprevir |
Hepatitis C, chronic |
Reimburse with clinical criteria and/or conditions |
Complete |
October 27, 2015 |
May 19, 2016 |
SR0454-000 |
Zeposia |
ozanimod |
Multiple Sclerosis, relapsing - remitting |
|
Active |
August 25, 2020 |
|
SR0652-000 |
Zinbryta |
Daclizumab beta |
Multiple Sclerosis, relapsing-remitting |
Reimburse with clinical criteria and/or conditions |
Complete |
December 20, 2016 |
June 20, 2017 |
SR0508-000 |
Zolgensma |
onasemnogene abeparvovec |
Spinal muscular atrophy (SMA), pediatrics |
|
Active |
June 25, 2020 |
|
SG0649-000 |
Zolinza |
vorinostat |
Cutaneous T-cell lymphoma |
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer |
NotFiled |
|
|
|
Opdivo |
Nivolumab |
Metastatic non small cell lung cancer |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
October 29, 2015 |
June 3, 2016 |
PC0069-000 |
Blincyto |
Blinatumomab |
Acute Lymphoblastic Leukemia |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
August 24, 2015 |
April 1, 2016 |
PC0064-000 |
Jakavi |
Ruxolitinib |
Polycythemia vera |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
August 27, 2015 |
March 3, 2016 |
PC0065-000 |
Adcetris |
Brentuximab vedotin |
|
|
Notification to Implement Issued |
March 15, 2013 |
December 5, 2013 |
PC0021-000 |
Arzerra |
Ofatumumab |
|
|
Notification to Implement Issued |
April 14, 2014 |
January 29, 2015 |
PC0038-000 |
Giotrif |
Afatinib |
|
|
Notification to Implement Issued |
June 7, 2013 |
May 2, 2014 |
PC0032-000 |
Kadcyla |
Trastuzumab emtansine |
|
|
Notification to Implement Issued |
March 15, 2013 |
January 10, 2014 |
PC0024-000 |
Nexavar |
Sorafenib |
|
|
Notification to Implement Issued |
December 19, 2014 |
July 16, 2015 |
PC0049-000 |
Revlimid |
Lenalidomide |
|
|
Notification to Implement Issued |
April 5, 2013 |
October 22, 2013 |
PC0029-000 |
Treanda (in combination with rituximab) |
Bendamustine hydrochloride |
|
|
Withdrawn |
June 27, 2014 |
|
PC0040-000 |
Tykerb (in combination with Letrozole) |
Lapatinib |
|
|
Notification to Implement Issued |
December 14, 2012 |
July 5, 2013 |
PC0019-000 |
Votrient |
Pazopanib hydrochloride |
|
|
Notification to Implement Issued Resubmission Complete |
July 14, 2011 |
January 5, 2012 |
PC0000-000 |
Xalkori |
Crizotinib |
|
|
Notification to Implement Issued |
February 17, 2015 |
July 21, 2015 |
PC0054-000 |
Zytiga |
Abiraterone acetate |
|
|
Notification to Implement Issued |
March 28, 2013 |
October 22, 2013 |
PC0028-000 |
Adcetris |
Brentuximab vedotin |
|
|
Withdrawn |
April 5, 2016 |
|
PC0086-000 |
Onivyde |
Nanoliposomal Irinotecan |
|
|
File-Closed Not Submitted |
|
|
PC0096-000 |
Mylotarg |
Gemtuzumab Ozogamicin |
Acute Myeloid Leukemia (AML) |
|
Notification to Implement Issued |
August 9, 2019 |
April 2, 2020 |
PC0190-000 |
Bosulif (RFA) |
Bosutinib |
Chronic Myeloid Leukemia |
|
Notification to Implement Issued |
April 8, 2019 |
|
PA0002-000 |
Unituxin |
Dinutuximab |
Neuroblastoma |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
October 1, 2018 |
March 26, 2019 |
PC0154-000 |
Xalkori |
Crizotinib |
ROS1-positive advanced non-small cell lung cancer (NSCLC) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
October 30, 2018 |
May 23, 2019 |
PC0151-000 |
Keytruda |
Pembrolizumab |
Nonsquamous NSCLC |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
September 14, 2018 |
May 31, 2019 |
PC0153-000 |
Keytruda |
Pembrolizumab |
MUC First line |
Do not reimburse |
Notification to Implement Issued |
February 20, 2019 |
October 3, 2019 |
PC0177-000 |
TBD |
Rituximab |
|
|
File-Closed Not Submitted |
|
|
PC0180-000 |
Opdivo |
Nivolumab |
Metastatic Hepatocellular Carcinoma (HCC) |
Do not reimburse |
Notification to Implement Issued |
May 8, 2018 |
November 29, 2018 |
PC0134-000 |
Blincyto |
Blinatumomab |
|
|
Withdrawn |
June 29, 2018 |
|
PC0143-000 |
Revlimid |
Lenalidomide |
Multiple Myeloma (+bortezomib+dex) |
Do not reimburse |
Notification to Implement Issued |
|
June 19, 2019 |
PC0141-000 |
Lenvima |
Lenvatinib |
Hepatocellular Carcinoma (HCC) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
February 8, 2019 |
July 24, 2019 |
PC0175-000 |
Vectibix |
Panitumumab |
Left Sided Metastatic Colorectal Cancer (mCRC) |
Do not reimburse |
Notification to Implement Issued |
September 8, 2017 |
March 29, 2018 |
PC0118-000 |
Gazyva |
Obinutuzumab |
Follicular Lymphoma (previously untreated) |
Do not reimburse |
Notification to Implement Issued |
March 15, 2018 |
November 1, 2018 |
PC0126-000 |
Darzalex |
Daratumumab |
Multiple Myeloma |
Do not reimburse |
Notification to Implement Issued |
April 21, 2016 |
December 1, 2016 |
PC0079-000 |
Lynparza (Resubmission) |
Olaparib |
Ovarian Cancer |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
March 17, 2017 |
September 20, 2017 |
PC0103-000 |
Opdivo |
Nivolumab |
Squamous Cell Carcinoma of Head and Neck (SCCHN) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
January 31, 2017 |
August 31, 2017 |
PC0095-000 |
Ninlaro |
Ixazomib |
Multiple Myeloma |
Do not reimburse |
Notification to Implement Issued |
December 16, 2016 |
June 29, 2017 |
PC0088-000 |
Imbruvica |
Ibrutinib |
|
|
Not Filed |
|
|
|
Kisqali |
Ribociclib |
HR+, HER2- advanced or metastatic breast cancer |
|
Notification to Implement Issued |
August 26, 2019 |
June 4, 2020 |
PC0194-000 |
Lonsurf |
Trifluridine-Tipiracil |
Gastric Cancer |
|
Notification to Implement Issued |
September 3, 2019 |
March 24, 2020 |
PC0197-000 |
Odomzo |
Sonidegib |
Basal Cell Carcinoma |
|
Under Review |
June 19, 2020 |
|
PC0215-000 |
Opdivo in combination with Yervoy |
Nivolumab in combination with Ipilimumab |
NSCLC |
|
Under Review |
June 23, 2020 |
|
PC0218-000 |
Cabometyx |
Cabozantinib |
HCC |
|
Notification to Implement Issued |
October 16, 2019 |
April 22, 2020 |
PC0186-000 |
Rozlytrek |
Entrectinib |
ROS1-positive NSCLC |
|
Notification to Implement Issued |
January 8, 2020 |
January 27, 2021 |
PC0206-000 |
Calquence |
Acalabrutinib |
Chronic Lymphocytic Leukemia (CLL) |
|
Notification to Implement Issued |
April 7, 2020 |
November 17, 2020 |
PC0211-000 |
Alecensaro |
Alectinib |
Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
August 18, 2017 |
March 29, 2018 |
PC0114-000 |
Bavencio |
Avelumab |
metastatic Merkel Cell Carcinoma (mMCC) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
October 10, 2017 |
March 21, 2018 |
PC0124-000 |
Kyprolis |
Carfilzomib |
Multiple Myeloma (relapsed) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
September 9, 2016 |
March 30, 2017 |
PC0084-000 |
Perjeta-Herceptin Combo Pack |
Pertuzumab-Trastuzumab Combo Pack |
Early Breast Cancer |
Do not reimburse |
Notification to Implement Issued |
April 9, 2018 |
November 29, 2018 |
PC0127-000 |
Erbitux |
Cetuximab |
|
|
File-Closed Not Submitted |
|
|
PC0128-000 |
Tafinlar & Mekinist in combo |
Dabrafenib & Trametinib in combo |
Non-Small Cell Lung Cancer |
Do not reimburse |
Notification to Implement Issued |
March 31, 2017 |
November 2, 2017 |
PC0106-000 |
Vizimpro |
Dacomitinib |
Non-Small Cell Lung Cancer |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
September 19, 2018 |
May 31, 2019 |
PC0129-000 |
Tafinlar & Mekinist in combo |
Dabrafenib & Trametinib in combo |
Melanoma Adjuvant Therapy |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
September 21, 2018 |
May 3, 2019 |
PC0152-000 |
Ibrance (with Faslodex) |
Palbociclib (with Fulvestrant) |
Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
September 28, 2018 |
May 3, 2019 |
PC0150-000 |
Velcade |
Bortezomib |
|
|
Notification to Implement Issued |
October 29, 2012 |
March 25, 2013 |
PC0016-000 |
Votrient |
Pazopanib hydrochloride |
|
|
Notification to Implement Issued Original Submission Complete |
February 20, 2013 |
August 29, 2013 |
PC0022-000 |
Xtandi |
Enzalutamide |
|
|
Notification to Implement Issued |
October 2, 2014 |
June 22, 2015 |
PC0044-000 |
Avastin |
Bevacizumab |
|
|
Notification to Implement Issued |
October 27, 2014 |
March 23, 2015 |
PC0045-000 |
Adcetris |
Brentuximab vedotin |
|
|
Notification to Implement Issued |
March 14, 2013 |
August 29, 2013 |
PC0020-000 |
Avastin (with capecitabine) |
Bevacizumab |
|
|
Notification to Implement Issued |
February 18, 2015 |
July 21, 2015 |
PC0055-000 |
Bosulif |
Bosutinib |
|
|
Notification to Implement Issued |
May 30, 2014 |
April 21, 2015 |
PC0039-000 |
Halaven |
Eribulin Mesylate |
|
|
Notification to Implement Issued |
February 9, 2012 |
August 2, 2012 |
PC0005-000 |
Perjeta Herceptin Combo Pack |
Pertuzumab |
|
|
Notification to Implement Issued |
November 2, 2012 |
August 1, 2013 |
PC0018-000 |
Stivarga (CRC) |
Regorafenib |
|
|
Notification to Implement Issued |
March 22, 2013 |
November 15, 2013 |
PC0026-000 |
Treanda |
Bendamustine hydrochloride |
|
|
Notification to Implement Issued |
April 24, 2012 |
November 29, 2012 |
PC0011-000 |
Imbruvica |
Ibrutinib |
Mantle Cell Lymphoma (relapsed/refractory) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
January 29, 2016 |
July 19, 2016 |
PC0073-000 |
Afinitor |
Everolimus |
Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
May 30, 2016 |
December 1, 2016 |
PC0083-000 |
Zydelig |
Idelalisib |
Follicular Lymphoma |
Do not reimburse |
Notification to Implement Issued |
April 12, 2016 |
September 29, 2016 |
PC0075-000 |
Vectibix |
Panitumumab |
|
|
Notification to Implement Issued |
April 15, 2015 |
December 3, 2015 |
PC0060-000 |
Lutathera |
Lutetium Lu 177 dotatate |
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
July 30, 2018 |
August 1, 2019 |
PC0142-000 |
Zejula |
Niraparib |
Ovarian Cancer |
|
Notification to Implement Issued |
February 7, 2020 |
September 3, 2020 |
PC0203-000 |
Lynparza |
Olaparib |
Newly Diagnosed OC |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
April 18, 2019 |
December 5, 2019 |
PC0174-000 |
Ninlaro |
Ixazomib |
Multiple Myeloma (2nd-beyond) |
Do not reimburse |
Notification to Implement Issued |
November 30, 2018 |
July 5, 2019 |
PC0164-000 |
Keytruda |
Pembrolizumab |
Melanoma Adjuvant Treatment |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
December 13, 2018 |
August 1, 2019 |
PC0168-000 |
Ogivri |
Trastuzumab |
|
|
Withdrawn |
December 18, 2018 |
|
PC0169-000 |
Adcetris |
Brentuximab Vedotin |
peripheral T-cell lymphoma (PTCL) |
|
Notification to Implement Issued |
October 8, 2019 |
June 4, 2020 |
PC0199-000 |
Xospata |
Gilteritinib |
|
|
Notification to Implement Issued |
October 28, 2019 |
May 20, 2020 |
PC0202 -000 |
Nubeqa |
Darolutamide |
non-metastatic castration resistant prostate cancer (nmCRPC) |
|
Notification to Implement Issued |
August 27, 2019 |
April 22, 2020 |
PC0196-000 |
Atriance |
Nelarabine |
|
|
File-Closed Not Submitted |
|
|
PC0170-000 |
Idhifa |
Enasidenib |
Acute myeloid leukemia (AML) |
Do not reimburse |
Notification to Implement Issued |
April 5, 2019 |
October 31, 2019 |
PC0144-000 |
Oncaspar |
Pegaspargase |
|
|
Not Filed |
|
|
|
Zytiga (Resubmission) |
Abiraterone |
Prostate Cancer Resubmission |
|
Suspended |
July 29, 2019 |
|
PC0201-000 |
Daurismo |
Glasdegib |
Acute Myeloid Leukemia (AML) |
|
Notification to Implement Issued |
May 6, 2020 |
January 8, 2021 |
PC0207-000 |
Afinitor |
Everolimus |
|
|
Notification to Implement Issued |
February 27, 2012 |
August 30, 2012 |
PC0007-000 |
Avastin |
Bevacizumab |
|
|
Notification to Implement Issued |
November 28, 2014 |
June 4, 2015 |
PC0047-000 |
Erbitux |
Cetuximab |
|
|
Notification to Implement Issued |
June 10, 2013 |
January 10, 2014 |
PC0031-000 |
Inlyta |
Axitinib |
|
|
Notification to Implement Issued |
August 16, 2012 |
March 7, 2013 |
PC0013-000 |
Perjeta or Perjeta-Herceptin Combo Pack |
Pertuzumab |
|
|
Notification to Implement Issued |
December 19, 2014 |
July 16, 2015 |
PC0050-000 |
Stivarga (GIST) |
Regorafenib |
|
|
Notification to Implement Issued |
October 11, 2013 |
May 2, 2014 |
PC0034-000 |
Sutent |
Sunitinib malate |
|
|
Notification to Implement Issued |
November 7, 2011 |
May 3, 2012 |
PC0004-000 |
Treanda |
Bendamustine hydrochloride |
|
|
Notification to Implement Issued |
April 24, 2012 |
February 19, 2013 |
PC0011-000 |
Votrient |
Pazopanib Hydrochloride |
|
|
Notification to Implement Issued |
June 4, 2012 |
November 29, 2012 |
PC0009-000 |
Xtandi |
Enzalutamide |
|
|
Notification to Implement Issued |
March 4, 2013 |
July 23, 2013 |
PC0023-000 |
Imbruvica |
Ibrutinib |
|
|
Notification to Implement Issued |
August 15, 2014 |
March 5, 2015 |
PC0043-000 |
Verzenio |
Abemaciclib |
Metastatic Breast Cancer |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
December 3, 2018 |
July 5, 2019 |
PC0161-000 |
Zytiga |
Abiraterone |
|
|
Withdrawn |
February 25, 2019 |
|
PC0166-000 |
Darzalex |
Daratumumab |
BMP for Multiple Myeloma (newly diagnosed) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
January 4, 2019 |
August 29, 2019 |
PC0148-000 |
Alecensaro |
Alectinib |
Locally advanced or metastatic ALK+ NSCLC (first line) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
January 15, 2018 |
July 25, 2018 |
PC0125-000 |
Lenvima |
Lenvatinib |
|
|
Notification to Implement Issued |
June 8, 2018 |
January 4, 2019 |
PC0140 -000 |
Demylocan |
Decitabine |
|
|
Not Filed |
|
|
|
Kadcyla |
Trastuzumab Emtansine |
Early Breast Cancer (EBC) |
Reimburse |
Notification to Implement Issued |
July 2, 2019 |
January 22, 2020 |
PC0182-000 |
Truxima |
Rituximab |
|
|
File-Closed Not Submitted |
|
|
PC0184-000 |
Stivarga |
Regorafenib |
Unresectable Hepatocellular Carcinoma (HCC) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
October 12, 2017 |
April 18, 2018 |
PC0119-000 |
Kisqali |
Ribociclib |
Advanced or Metastatic Breast Cancer |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
October 17, 2017 |
April 18, 2018 |
PC0112-000 |
Tecentriq |
Atezolizumab |
Small Cell Lung Cancer (SCLC) |
Do not reimburse |
Notification to Implement Issued |
March 4, 2019 |
January 30, 2020 |
PC0156-000 |
Lonsurf |
Trifluridine and Tipiracil |
Metastatic Colorectal Cancer |
Do not reimburse |
Notification to Implement Issued |
November 6, 2017 |
July 6, 2018 |
PC0122-000 |
Folotyn |
Pralatrexate |
Peripheral T-Cell Lymphoma (PTCL) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
June 1, 2018 |
April 4, 2019 |
PC0138-000 |
Tecentriq & Avastin |
Atezolizumab & Bevacizumab |
NSQ-NSCLC |
|
Notification to Implement Issued |
November 18, 2019 |
July 3, 2020 |
PC0155-000 |
Venclexta |
Venetoclax Obinutuzumab |
Obinutuzumab for CLL |
|
Notification to Implement Issued |
April 17, 2020 |
November 17, 2020 |
PC0212-000 |
Keytruda |
Pembrolizumab |
|
|
Not Filed |
|
|
|
Rydapt |
Midostaurin |
Systemic Mastocytosis |
|
Notification to Implement Issued |
August 13, 2019 |
April 2, 2020 |
PC0193-000 |
Imbruvica |
Ibrutinib |
|
|
Not Filed |
|
|
|
Darzalex |
Daratumumab |
Rd for MM |
|
Notification to Implement Issued |
July 17, 2019 |
March 5, 2020 |
PC0189-000 |
TBD |
Trastuzumab |
|
|
File-Closed Not Submitted |
|
|
PC0160-000 |
Inlyta (RFA) |
Axitinib |
Metastatic Renal Cell Carcinoma |
|
Notification to Implement Issued |
April 18, 2017 |
|
PA0001-000 |
Keytruda |
Pembrolizumab |
classical Hodgkin Lymphoma (cHL) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
July 7, 2017 |
January 5, 2018 |
PC0109-000 |
Rydapt |
Midostaurin |
Acute Myeloid Leukemia |
Reimburse |
Notification to Implement Issued |
June 12, 2017 |
December 19, 2017 |
PC0108-000 |
Ibrance Resubmission |
Palbociclib |
Advanced breast cancer |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
June 10, 2016 |
November 21, 2016 |
PC0093-000 |
Opdivo & Yervoy in combo |
Nivolumab & Ipilimumab in combo |
Metastatic Melanoma |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
November 30, 2016 |
November 30, 2017 |
PC0098-000 |
Gazyva |
Obinutuzumab |
Follicular Lymphoma |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
November 4, 2016 |
June 2, 2017 |
PC0091-000 |
Tagrisso |
Osimertinib |
Non-Small Cell Lung Cancer |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
April 1, 2016 |
May 4, 2017 |
PC0076-000 |
Zykadia |
Ceritinib |
|
|
Notification to Implement Issued |
June 5, 2015 |
December 3, 2015 |
PC0062-000 |
Opdivo |
Nivolumab |
Metastatic Melanoma |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
August 13, 2015 |
April 1, 2016 |
PC0063-000 |
Opdivo |
Nivolumab |
Metastatic Renal Cell Carcinoma |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
February 24, 2016 |
September 1, 2016 |
PC0074-000 |
Blincyto |
Blinatumomab |
|
|
Notification to Implement Issued |
February 24, 2017 |
August 23, 2017 |
PC0099 -000 |
Polivy |
Polatuzumab Vedotin |
Diffuse large B-cell lymphoma (DLBCL) |
|
Under Review |
September 29, 2020 |
|
PC0227-000 |
Alunbrig |
Brigatinib |
(ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) |
|
Under Review |
September 30, 2020 |
|
PC0230-000 |
Afinitor |
Everolimus |
|
|
Notification to Implement Issued |
September 5, 2012 |
March 25, 2013 |
PC0014-000 |
Erivedge |
Vismodegib |
|
|
Notification to Implement Issued |
June 14, 2013 |
January 10, 2014 |
PC0015-000 |
Istodax |
Romidepsin |
|
|
Notification to Implement Issued |
December 1, 2014 |
May 19, 2015 |
PC0048-000 |
Pomalyst |
Pomalidomide |
|
|
Notification to Implement Issued |
January 13, 2014 |
July 31, 2014 |
PC0036-000 |
Stivarga Resubmission (CRC) |
Regorafenib |
|
|
Notification to Implement Issued |
December 19, 2014 |
July 16, 2015 |
PC0046-000 |
Sylvant |
Siltuximab |
|
|
Notification to Implement Issued |
January 30, 2015 |
June 22, 2015 |
PC0052-000 |
Treanda |
Bendamustine hydrochloride |
|
|
Notification to Implement Issued |
April 24, 2012 |
November 29, 2012 |
PC0010-000 |
Xalkori |
Crizotinib |
|
|
Notification to Implement Issued Original Submission Complete |
March 26, 2012 |
October 4, 2012 |
PC0008-000 |
Yervoy |
Ipilimumab |
|
|
Notification to Implement Issued |
December 1, 2011 |
April 18, 2012 |
PC0003-000 |
Zaltrap |
Aflibercept |
|
|
Notification to Implement Issued |
November 26, 2013 |
September 5, 2014 |
PC0035-000 |
Tafinlar & Mekinist in combo |
Dabrafenib & Trametinib in combo |
|
|
Notification to Implement Issued |
February 13, 2015 |
July 21, 2015 |
PC0053-000 |
Zykadia (Resubmission) |
Ceritinib |
metastatic non-small cell lung cancer |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
October 19, 2016 |
March 21, 2017 |
PC0094-000 |
Lorbrena |
Lorlatinib |
Non-Small Cell Lung Cancer (NSCLC) |
Do not reimburse |
Notification to Implement Issued |
June 11, 2019 |
January 30, 2020 |
PC0183-000 |
Zevalin |
Ibritumomab tiuxetan |
|
|
Not Filed |
|
|
|
Opdivo in combination with Yervoy |
Nivolumab in combination with Ipilimumab |
Advanced or Metastatic Renal Cell Carcinoma (RCC). |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
April 26, 2018 |
November 1, 2018 |
PC0132-000 |
Erleada |
Apalutamide |
non-metastatic castrate resistant prostate cancer (nm-CRPC) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
April 16, 2018 |
November 1, 2018 |
PC0133-000 |
Kisqali |
Ribociclib with Fulvestrant |
+Fulvestrant for HR+, HER2- advanced or metastatic breast cancer |
|
Notification to Implement Issued |
August 26, 2019 |
April 22, 2020 |
PC0195-000 |
Tecentriq |
Atezolizumab |
|
|
Withdrawn |
October 2, 2019 |
|
PC0171-000 |
Keytruda |
Pembrolizumab |
For locally advanced or metastatic urothelial carcinoma |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
July 24, 2017 |
March 2, 2018 |
PC0117-000 |
Venclexta in combo Rituximab |
Venetoclax |
Chronic Lymphocytic Leukemia (CLL) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
October 24, 2018 |
May 31, 2019 |
PC0162-000 |
Opdivo |
Nivolumab |
Melanoma Adjuvant Therapy |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
August 27, 2018 |
March 7, 2019 |
PC0147-000 |
Imfinzi |
Durvalumab |
Unresectable Non-Small Cell Lung Cancer (NSCLC) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
September 21, 2018 |
May 3, 2019 |
PC0131-000 |
Keytruda |
Pembrolizumab |
Squamous NSCLC |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
February 8, 2019 |
January 3, 2020 |
PC0176-000 |
Tecentriq |
Atezolizumab |
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
December 15, 2017 |
June 20, 2018 |
PC0115-000 |
Vitrakvi |
Larotrectinib |
NTRKplus solid tumours |
Do not reimburse |
Notification to Implement Issued |
February 25, 2019 |
October 31, 2019 |
PC0159-000 |
TBD |
Bevacizumab |
|
|
File Closed |
March 14, 2019 |
|
PC0178-000 |
Imbruvica |
Ibrutinib |
Chronic Lymphocytic Leukemia (previously untreated) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
April 20, 2016 |
November 3, 2016 |
PC0085-000 |
Venclexta |
Venetoclax |
|
|
Withdrawn |
July 8, 2016 |
|
PC0087-000 |
Lenvima |
Lenvatinib |
Differentiated Thyroid Cancer |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
April 18, 2016 |
September 20, 2016 |
PC0080-000 |
Imbruvica |
Ibrutinib |
Waldenstrom's Macroglobulinemia |
Do not reimburse |
Pending |
April 21, 2016 |
November 3, 2016 |
PC0082-000 |
Caprelsa |
Vandetanib |
Medullary Thyroid Cancer |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
August 15, 2016 |
March 30, 2017 |
PC0090-000 |
Keytruda |
Pembrolizumab |
|
|
Notification to Implement Issued |
April 16, 2015 |
November 16, 2015 |
PC0058-000 |
Yondelis |
Trabectedin |
Metastatic Liposarcoma or Leiomyosarcoma |
Do not reimburse |
Notification to Implement Issued |
December 22, 2015 |
August 5, 2016 |
PC0071-000 |
Cotellic |
Cobimetinib |
Metastatic melanoma |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
December 11, 2015 |
June 30, 2016 |
PC0070-000 |
Kyprolis (with lenalidomide) |
Carfilzomib (with lenalidomide) |
Multiple Myeloma |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
December 11, 2015 |
June 21, 2016 |
PC0067-000 |
Lartruvo |
Olaratumab |
Advanced Soft Tissue Sarcoma |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
October 26, 2017 |
April 18, 2018 |
PC0111-000 |
Opdivo |
Nivolumab |
classical Hodgkin Lymphoma (cHL) after failure of ASCT |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
September 29, 2017 |
May 3, 2018 |
PC0120-000 |
Darzalex |
Daratumumab |
Multiple Myeloma (second-line) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
March 3, 2017 |
October 5, 2017 |
PC0104-000 |
Adcetris |
Brentuximab Vedotin |
Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) |
|
Notification to Implement Issued |
April 2, 2020 |
December 3, 2020 |
PC0214-000 |
Calquence |
Acalabrutinib |
Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) |
|
Notification to Implement Issued |
April 7, 2020 |
January 8, 2021 |
PC0210-000 |
Tecentriq & Avastin |
Atezolizumab & Bevacizumab |
Hepatocellular Carcinoma (HCC) |
|
Notification to Implement Issued |
May 21, 2020 |
November 17, 2020 |
PC0217-000 |
Onivyde |
Irinotecan Liposome |
Metastatic Pancreatic Cancer |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
April 27, 2017 |
January 5, 2018 |
PC0107-000 |
Tagrisso |
Osimertinib |
Non-Small Cell Lung Cancer (NSCLC) (first line) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
May 16, 2018 |
January 4, 2019 |
PC0137-000 |
Beleodaq |
Belinostat |
|
|
Withdrawn |
June 29, 2018 |
|
PC0139-000 |
Keytruda |
Pembrolizumab |
Non-Small Cell Lung Cancer |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
April 21, 2016 |
November 3, 2016 |
PC0077-000 |
Alecensaro |
Alectinib |
Non-Small Cell Lung Cancer |
Do not reimburse |
Notification to Implement Issued |
October 3, 2016 |
May 4, 2017 |
PC0092-000 |
Blincyto (Resubmission) |
Blinatumomab |
Acute Lymphoblastic Leukemia (ALL) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
February 24, 2017 |
August 31, 2017 |
PC0097-000 |
Venclexta |
Venetoclax |
Chronic Lymphocytic Leukemia |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
July 10, 2017 |
March 2, 2018 |
PC0105-000 |
TBD |
Cabozantinib |
|
|
Withdrawn |
October 6, 2017 |
|
PC0123-000 |
Besponsa |
Inotuzumab Ozogamicin |
Acute Lymphoblastic Leukemia (ALL) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
November 13, 2017 |
July 6, 2018 |
PC0121-000 |
Pomalyst |
Pomalidomide |
Multiple Myeloma |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
March 15, 2019 |
September 18, 2019 |
PC0165-000 |
Nerlynx |
Neratinib |
ERBB2-positive breast cancer |
Do not reimburse |
Notification to Implement Issued |
April 18, 2019 |
December 5, 2019 |
PC0172-000 |
Lynparza |
Olaparib |
Ovarian Cancer |
Do not reimburse |
Notification to Implement Issued |
April 1, 2016 |
September 29, 2016 |
PC0081-000 |
Cyramza |
Ramucirumab |
|
|
File-Closed Not Submitted |
|
|
PC0078-000 |
Adcetris |
Brentuximab Vedotin |
HL at high risk of relapse or progression post-ASCT |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
August 10, 2017 |
February 21, 2018 |
PC0116-000 |
Faslodex |
Fulvestrant |
Locally advanced or metastatic breast cancer |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
July 17, 2017 |
February 1, 2018 |
PC0110-000 |
Rituxan |
Rituximab |
Acute Lymphoblastic Leukemia |
Do not reimburse |
Notification to Implement Issued |
February 13, 2017 |
August 31, 2017 |
PC0102-000 |
Cabometyx |
Cabozantinib |
Renal Cell Carcinoma (RCC) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
September 17, 2018 |
February 20, 2019 |
PC0163-000 |
Xtandi |
Enzalutamide |
Non-metastatic castration-resistant prostate cancer (nm-CRPC) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
September 24, 2018 |
March 26, 2019 |
PC0149-000 |
Adcetris (Resubmission) |
Brentuximab Vedotin |
Hodgkin lymphoma (HL) |
Do not reimburse |
Notification to Implement Issued |
August 27, 2018 |
March 7, 2019 |
PC0145-000 |
Blincyto |
Blinatumomab |
Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
August 31, 2018 |
April 4, 2019 |
PC0146-000 |
Alunbrig |
Brigatinib |
NSCLC |
Do not reimburse |
Notification to Implement Issued |
December 5, 2018 |
August 1, 2019 |
PC0167-000 |
Mvasi |
Bevacizumab |
mCRC NSCLC Biosimilar |
|
Final Biosimilar Dossier Issued |
October 3, 2018 |
|
PC0158-000 |
Libtayo |
Cemiplimab |
Advanced Cutaneous Squamous Cell Carcinoma (CSCC) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
July 9, 2019 |
January 22, 2020 |
PC0187-000 |
Abraxane |
Nab-paclitaxel |
|
|
Notification to Implement Issued |
February 14, 2014 |
September 23, 2014 |
PC0037-000 |
Alimta |
Pemetrexed |
|
|
Notification to Implement Issued |
May 31, 2013 |
November 19, 2013 |
PC0027-000 |
Gazyva |
Obinutuzumab |
|
|
Notification to Implement Issued |
August 11, 2014 |
January 27, 2015 |
PC0041-000 |
Jakavi |
Ruxolitinib |
|
|
Notification to Implement Issued |
June 25, 2012 |
January 14, 2013 |
PC0012-000 |
Mekinist |
Trametinib |
|
|
Notification to Implement Issued |
May 6, 2013 |
October 22, 2013 |
PC0030-000 |
Proleukin |
Aldesleukin (IL-2) |
|
|
Notification to Implement Issued |
January 30, 2015 |
June 22, 2015 |
PC0051-000 |
Tafinlar |
Dabrafenib |
|
|
Notification to Implement Issued |
March 18, 2013 |
December 5, 2013 |
PC0025-000 |
Trisenox |
Arsenic Trioxide |
|
|
Notification to Implement Issued |
August 30, 2013 |
February 18, 2014 |
PC0033-000 |
Xalkori |
Crizotinib |
|
|
Notification to Implement Issued Original Submission Complete |
October 23, 2012 |
May 2, 2013 |
PC0017-000 |
Yervoy |
Ipilimumab |
|
|
Notification to Implement Issued |
August 15, 2014 |
December 22, 2014 |
PC0042-000 |
Zelboraf |
Vemurafenib |
|
|
Notification to Implement Issued |
December 6, 2011 |
June 1, 2012 |
PC0006-000 |
Avastin |
Bevacizumab |
Platinum Resistant Ovarian Cancer |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
October 29, 2015 |
May 5, 2016 |
PC0066-000 |
Ibrance |
Palbociclib |
|
|
Suspended |
November 11, 2015 |
|
PC0068-000 |
Cyramza |
Ramucirumab |
|
|
Notification to Implement Issued |
April 15, 2015 |
October 29, 2015 |
PC0059-000 |
Iclusig |
Ponatinib |
|
|
Notification to Implement Issued |
March 13, 2015 |
October 1, 2015 |
PC0056 -000 |
Zydelig |
Idelalisib |
|
|
Notification to Implement Issued |
April 7, 2015 |
August 18, 2015 |
PC0057-000 |
Revlimid |
Lenalidomide |
|
|
Notification to Implement Issued |
May 4, 2015 |
December 3, 2015 |
PC0061-000 |
Keytruda |
Pembrolizumab |
Advanced non-small cell lung carcinoma (first line) |
Reimburse with clinical criteria and/or conditions |
Notification to Implement Issued |
December 12, 2016 |
August 23, 2017 |
PC0101-000 |
Avastin |
Bevacizumab |
|
|
Withdrawn |
December 16, 2016 |
|
PC0100-000 |
Lonsurf |
Trifluridine and Tipiracil |
mCRC Resubmission |
Do not reimburse |
Notification to Implement Issued |
January 21, 2019 |
August 29, 2019 |
PC0173-000 |
TBD |
Entrectinib |
|
|
Withdrawn |
July 29, 2019 |
|
PC0157-000 |
Keytruda |
Pembrolizumab |
Renal Cell Carcinoma (RCC) |
|
Notification to Implement Issued |
August 2, 2019 |
April 2, 2020 |
PC0185-000 |
Xtandi |
Enzalutamide |
mHSPC |
|
Notification to Implement Issued |
February 24, 2020 |
September 23, 2020 |
PC0209-000 |
Keytruda |
Pembrolizumab |
|
|
Not Filed |
|
|
|
Erleada |
Apalutamide |
metastatic castration-sensitive prostate cancer (mCSPC) |
|
Notification to Implement Issued |
October 15, 2019 |
April 22, 2020 |
PC0200-000 |
Blincyto |
Blinatumomab |
MRD+ ALL Resubmission |
|
Notification to Implement Issued |
January 20, 2020 |
October 29, 2020 |
PC0204-000 |
Adcetris |
Brentuximab Vedotin |
Primary cutaneous anaplastic large cell Lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) |
|
Notification to Implement Issued |
March 30, 2020 |
December 3, 2020 |
PC0213-000 |
Lynparza |
Olaparib |
|
|
Not Filed |
|
|
|
Keytruda |
Pembrolizumab |
head and neck squamous cell carcinoma (HNSCC) |
|
Notification to Implement Issued |
May 1, 2020 |
December 22, 2020 |
PC0216-000 |
Sarclisa |
Isatuximab |
Multiple Myeloma |
|
Under Review |
August 17, 2020 |
|
PC0220-000 |
Lynparza |
Olaparib |
metastatic castration-resistant prostate cancer (mCRPC) |
|
Under Review |
September 22, 2020 |
|
PC0223-000 |
Inqovi |
Decitabine-Cedazuridine |
Myelodysplastic Syndromes (MDS) |
|
Under Review |
October 9, 2020 |
|
PC0228-000 |
Tafinlar and Mekinist |
Dabrafenib and Trametinib |
NSCLC BRAF V600 |
|
Under Review |
October 1, 2020 |
|
PC0226-000 |
Bavencio |
Avelumab |
Urothelial Carcinoma (UC) |
|
Under Review |
September 18, 2020 |
|
PC0225-000 |
Zejula |
Niraparib |
First Line OC |
|
Under Review |
September 21, 2020 |
|
PC0224-000 |